US20130317036A1 - Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions - Google Patents
Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions Download PDFInfo
- Publication number
- US20130317036A1 US20130317036A1 US13/991,286 US201113991286A US2013317036A1 US 20130317036 A1 US20130317036 A1 US 20130317036A1 US 201113991286 A US201113991286 A US 201113991286A US 2013317036 A1 US2013317036 A1 US 2013317036A1
- Authority
- US
- United States
- Prior art keywords
- active principle
- vitamin
- pharmaceutically acceptable
- leucine
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 226
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 165
- 239000011724 folic acid Substances 0.000 title claims abstract description 100
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 99
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960000304 folic acid Drugs 0.000 title claims abstract description 65
- 229960003401 ramipril Drugs 0.000 title claims abstract description 49
- 230000000324 neuroprotective effect Effects 0.000 title abstract description 8
- 230000003289 retinoprotective effect Effects 0.000 title abstract description 8
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims abstract description 56
- 230000004304 visual acuity Effects 0.000 claims abstract description 30
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 claims abstract description 25
- 230000000007 visual effect Effects 0.000 claims abstract description 18
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 13
- 208000001491 myopia Diseases 0.000 claims abstract description 13
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 10
- 201000010041 presbyopia Diseases 0.000 claims abstract description 10
- 230000004379 myopia Effects 0.000 claims abstract description 9
- 210000001525 retina Anatomy 0.000 claims abstract description 9
- 206010046851 Uveitis Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 77
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 69
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 60
- 241001465754 Metazoa Species 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 49
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 48
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 48
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 46
- 239000011777 magnesium Substances 0.000 claims description 46
- 229910052749 magnesium Inorganic materials 0.000 claims description 46
- 235000001055 magnesium Nutrition 0.000 claims description 46
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 45
- 239000011591 potassium Substances 0.000 claims description 45
- 229910052700 potassium Inorganic materials 0.000 claims description 45
- 235000007686 potassium Nutrition 0.000 claims description 45
- 239000008103 glucose Substances 0.000 claims description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 41
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 38
- 229930064664 L-arginine Natural products 0.000 claims description 38
- 235000014852 L-arginine Nutrition 0.000 claims description 38
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims description 38
- 229960000669 acetylleucine Drugs 0.000 claims description 37
- 230000004438 eyesight Effects 0.000 claims description 35
- 229940014144 folate Drugs 0.000 claims description 34
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 33
- 229930003268 Vitamin C Natural products 0.000 claims description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 33
- 239000000194 fatty acid Substances 0.000 claims description 33
- 229930195729 fatty acid Natural products 0.000 claims description 33
- 150000004665 fatty acids Chemical class 0.000 claims description 33
- 235000019154 vitamin C Nutrition 0.000 claims description 33
- 239000011718 vitamin C Substances 0.000 claims description 33
- 229930003779 Vitamin B12 Natural products 0.000 claims description 32
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 32
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 32
- 235000019163 vitamin B12 Nutrition 0.000 claims description 32
- 239000011715 vitamin B12 Substances 0.000 claims description 32
- 235000019158 vitamin B6 Nutrition 0.000 claims description 32
- 239000011726 vitamin B6 Substances 0.000 claims description 32
- 229940011671 vitamin b6 Drugs 0.000 claims description 32
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 239000002876 beta blocker Substances 0.000 claims description 29
- 229940097320 beta blocking agent Drugs 0.000 claims description 28
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 24
- 239000003889 eye drop Substances 0.000 claims description 24
- 229960002748 norepinephrine Drugs 0.000 claims description 24
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 24
- 229940012356 eye drops Drugs 0.000 claims description 23
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 22
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 21
- 239000005541 ACE inhibitor Substances 0.000 claims description 20
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 20
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 19
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 19
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 17
- 206010013774 Dry eye Diseases 0.000 claims description 14
- 235000001727 glucose Nutrition 0.000 claims description 14
- 239000002997 ophthalmic solution Substances 0.000 claims description 14
- 229960002231 ramiprilat Drugs 0.000 claims description 14
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 claims description 13
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 12
- 229940054534 ophthalmic solution Drugs 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 10
- 206010023332 keratitis Diseases 0.000 claims description 10
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 201000001119 neuropathy Diseases 0.000 claims description 9
- 230000007823 neuropathy Effects 0.000 claims description 9
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 7
- 208000027073 Stargardt disease Diseases 0.000 claims description 7
- 230000002137 anti-vascular effect Effects 0.000 claims description 7
- 229940124548 retinoprotector Drugs 0.000 claims description 7
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims description 7
- 229960004617 sapropterin Drugs 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 239000006196 drop Substances 0.000 claims description 6
- 230000001067 neuroprotector Effects 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- -1 B4b Chemical compound 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 208000037849 arterial hypertension Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 208000021921 corneal disease Diseases 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000004377 improving vision Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 230000000626 neurodegenerative effect Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000033379 Chorioretinopathy Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 206010020675 Hypermetropia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 201000010183 Papilledema Diseases 0.000 claims description 4
- 206010033708 Papillitis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- 230000004305 hyperopia Effects 0.000 claims description 4
- 201000006318 hyperopia Diseases 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 201000002166 optic papillitis Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 125000003929 folic acid group Chemical group 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 abstract description 13
- 208000018769 loss of vision Diseases 0.000 abstract description 12
- 231100000864 loss of vision Toxicity 0.000 abstract description 12
- 230000004393 visual impairment Effects 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 9
- 230000007170 pathology Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 description 50
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 44
- 229960003136 leucine Drugs 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000032683 aging Effects 0.000 description 13
- 208000030533 eye disease Diseases 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 12
- 230000004382 visual function Effects 0.000 description 12
- 239000000556 agonist Substances 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229960003679 brimonidine Drugs 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 210000001742 aqueous humor Anatomy 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 229940105623 neo-synephrine Drugs 0.000 description 6
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 6
- 229960004605 timolol Drugs 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 229960003975 potassium Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- ZHQJVZLJDXWFFX-RPDRRWSUSA-N (6R)-L-erythro-6,7-dihydrobiopterin Chemical compound N1C(N)=NC(=O)C2=N[C@@H]([C@@H](O)[C@@H](O)C)CN=C21 ZHQJVZLJDXWFFX-RPDRRWSUSA-N 0.000 description 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 4
- 102400000967 Bradykinin Human genes 0.000 description 4
- 101800004538 Bradykinin Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 4
- 206010047141 Vasodilatation Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 229960003876 ranibizumab Drugs 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 3
- 229960002781 bisoprolol Drugs 0.000 description 3
- 230000004456 color vision Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 230000008397 ocular pathology Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 229960001528 oxymetazoline Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229960003407 pegaptanib Drugs 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 235000019159 vitamin B9 Nutrition 0.000 description 3
- 239000011727 vitamin B9 Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000014087 Chorioretinal disease Diseases 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 2
- WXNXCEHXYPACJF-SSDOTTSWSA-N N-acetyl-D-leucine Chemical compound CC(C)C[C@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-SSDOTTSWSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 229930003761 Vitamin B9 Natural products 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
- 229960002122 acebutolol Drugs 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 229960004324 betaxolol Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 229960001222 carteolol Drugs 0.000 description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 206010011005 corneal dystrophy Diseases 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 210000003717 douglas' pouch Anatomy 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- 229960003745 esmolol Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 229960004553 guanabenz Drugs 0.000 description 2
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 2
- 229960003602 guanethidine Drugs 0.000 description 2
- 229960002048 guanfacine Drugs 0.000 description 2
- QKIQJNNDIWGVEH-UUILKARUSA-N guanoxabenz Chemical compound ONC(/N)=N/N=C/C1=C(Cl)C=CC=C1Cl QKIQJNNDIWGVEH-UUILKARUSA-N 0.000 description 2
- 229960001016 guanoxabenz Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 2
- 229960000831 levobunolol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960005192 methoxamine Drugs 0.000 description 2
- 229960002704 metipranolol Drugs 0.000 description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 2
- 229960002035 penbutolol Drugs 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 229960000488 tizanidine Drugs 0.000 description 2
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- MEZCUMCMVYZPAH-UHFFFAOYSA-N 6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CC(F)C2=C1 MEZCUMCMVYZPAH-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010005178 Blindness day Diseases 0.000 description 1
- KEDYTOTWMPBSLG-UHFFFAOYSA-N CC(NC(CCC1=CC=CC=C1)C(=O)O)C(=O)N1C(C(=O)O)CC2CCCC21 Chemical compound CC(NC(CCC1=CC=CC=C1)C(=O)O)C(=O)N1C(C(=O)O)CC2CCCC21 KEDYTOTWMPBSLG-UHFFFAOYSA-N 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 0 N[c+]1nC2=C(N=C(CNC3=CC=C(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])C=C3)C=N2)C(=O)N1 Chemical compound N[c+]1nC2=C(N=C(CNC3=CC=C(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])C=C3)C=N2)C(=O)N1 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UDMBCSSLTHHNCD-DGPXGRDGSA-N [(2r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-DGPXGRDGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000001362 anti-vertigo Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 231100000826 degradation of vision Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003152 propanolamines Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229940035274 tobradex Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 108010080213 vascular factor Proteins 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to a composition and, in particular, to a cellprotective, neuroprotective and retinoprotective composition which is especially appropriate for maintaining or improving visual function (visual acuity and/or vision field).
- said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid.
- the invention also relates to the use of said composition for the prevention or the treatment of different types of disease(s) or disorder(s) and especially of cancers or of ophthalmologic disease(s) or disorders involving chorio-retinal and/or optic nerve, resulting in a progressive loss of vision (visual acuity and/or field of vision).
- Such effects on vision are observed, in particular, in glaucoma, macular degeneration, inherited retinal diseases, myopia, presbyopia, uveitis and diabetic retinopathy.
- a combination of angiotensin converting enzyme inhibitor for example, ramipril or ramiprilate
- folic acid or folate
- optionally one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B (tetrahydrobiopterin), L-arginine, w-3 fatty acids (omega 3 fatty acids), magnesium, potassium, glucose and/or amino-acids (for example, a leucine, and especially an acetyl-leucine), in appropriate amounts form a novel approach in the prevention and management of various diseases or disorders and, in particular, of ophthalmologic conditions such as glaucoma, glaucoma neuropathy, age related macular degeneration, inherited retinal dystrophies, myopia, presbyopia, diabetic retinopathy, or other diseases described herein.
- ophthalmologic conditions such as glaucoma, glaucoma neuropathy, age related macular degeneration, inherited retinal dystrophies, myopia, presbyopia
- the invention especially aims to provide compositions or medicaments (or drugs) and a kit intended for the prevention and/or the treatment of ophthalmologic diseases or disorders, which can improve visual function, in particular, the field of vision and/or visual acuity in patients suffering from neuropathies such as glaucoma, but also other chorioretinal disorders or deterioration of the optic nerve that may involve a vascular factor.
- ophthalmologic diseases that can be mentioned are:
- Age-related macular degeneration (ARMD)
- the invention is based, in particular, on the fact that when used to treat patients, Ramipril associated with a second particular active principle, for example, folic acid, causes not only an interruption—which until now has never been observed in patients treated for ophthalmologic diseases and especially diseases of the types mentioned herein—but moreover at least a partial inversion of the process of degradation of visual function, with an improvement in visual acuity and/or field of vision (usually both in visual acuity and field of vision).
- a second particular active principle for example, folic acid
- Ramipril or ramiprilate
- folic acid as well as other particular compounds and especially vitamin c, w-3 fatty acids and H4B augment the activity of Ramipril.
- the combination of Ramipril (or ramiprilate) with one or several of these active principles as discloses herein is more efficient to prevent or to treat some ocular pathologies and presents a more cell protective, neuroprotective and retinoprotective effect than each of these drugs used alone.
- the combinations of active principles disclosed herein are not limited to the applications mentioned herein. They can be employed successfully to prevent or stow down or even stop a “natural” decrease in visual acuity, field of vision or both at the same time. In particular, they can be used successfully to prevent and even reverse visual decline in an aging animal (especially an aging human or non human mammal) and especially physiologic visual decline.
- the invention can be applied successfully for the treatment of other types of diseases including cancer.
- Ramipril which is marketed, in particular, as Tritace®, Triatec®, Delix® or Altace®, has the following formula:
- Ramiprilate which results from de-esterfication of ramipril, has the following formula:
- Folic Acid also known as vitamin B9, vitamin M or folacin
- Folate (the naturally occurring form of folic acid) has the following formula:
- the present invention relates to a composition characterised in that it comprises at least two active principles chosen among an angiotensin-converting enzyme inhibitor, folic acid, folate, magnesium, potassium, glucose, amino-acids (especially a leucine and, in particular, an acetyl-leucine), L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- the composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid.
- composition of the invention can be used as medicament and, in particular, as a cell protector, a neuroprotector and/or a retinoprotector medicament. More especially, this composition is appropriate for use in the prevention and/or the treatment in an animal in need thereof of one or several disease(s) or disorder(s) chosen from: ophthalmologic conditions, cancers, arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infections).
- disease(s) or disorder(s) chosen from: ophthalmologic conditions, cancers, arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (for example, viral and especially HIV infection,
- the invention is also directed to a method of preventing and/or treating one or several disease(s) or disorder(s) in an animal in need thereof, and to a method for maintaining or improving vision and, in particular, the visual acuity and/or the field of vision in an animal in need thereof.
- Said methods comprise administering to said animal active principles as disclosed herein.
- the invention also relates to a kit appropriate to carry out a method of the invention, and especially to a kit comprising at least two active principles as disclosed herein, and, optionally, instructions for using said kit.
- Vision or “visual function” as used herein encompasses visual acuity (more especially near and/or far visual acuity) as well as contrast vision, color vision and field of vision (also called visual field herein).
- loss of vision or “degradation of visual function” as used herein includes partial or total loss of vision, and especially a partial or total loss in visual acuity (near and/or far visual acuity) and/or contrast vision and/or color vision and/or field of vision. It can result from a “natural” visual decline (i.e., it appears in the absence of any apparent eye disease or disorder), for example, in an aging animal, and/or from one or several ophthalmic condition(s) (in particular, an eye disorder and/or an eye disease) as disclosed herein.
- treating and “treatment” mean that an ophthalmologic condition (in particular, an eye disorder and/or an eye disease) is improved (at least partially) and, in particular, that the visual acuity and/or the contrast vision and/or the color vision and/or the field of vision of the treated animal is improved, or that the process of degradation of visual function is stopped.
- an ophthalmologic condition in particular, an eye disorder and/or an eye disease
- the visual acuity and/or the contrast vision and/or the color vision and/or the field of vision of the treated animal is improved, or that the process of degradation of visual function is stopped.
- ophthalmologic conditions encompasses ophthalmologic disorders and ophthalmologic diseases involving chorio-retinal and/or optic nerve, resulting in a progressive loss of vision.
- eye disorders encompasses changes in vision, in the appearance of the eye or having abnormal sensations in the eye. Eye disorders include optic nerve disorders and chorio-retinal disorders, as well as trauma such as injuries to the eye, and especially disorders resulting in a progressive visual degradation or loss of vision.
- ophthalmologic diseases means any disease of the eye and, in particular, any disease of the eye resulting in a progressive loss of vision. This terminology encompasses the following diseases of the eye:
- animal as used herein includes mammalians, in particular, humans and non human mammalians, and birds.
- mammalian or “mammal” as used herein encompasses any of various warm-blooded vertebrate animals of the class Mammalia, including humans and non human mammals, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young.
- topical administration it is meant herein an administration which has a local effect. This term includes especially a sub-tenonian administration, or an administration to the eye (especially on infra- or extra-ocular administration).
- the administration to the eye can be performed, for example, by applying active principle(s) as disclosed herein (which can be, for example, in the form of an ophthalmologic solution, an ointment or eye drops) to the outside surface of the eye, i.e., by contacting the eye and especially the cornea with said active principle(s).
- active principle(s) as disclosed herein which can be, for example, in the form of an ophthalmologic solution, an ointment or eye drops
- the administration to the eye can be performed by injecting active principle(s) into the eye and especially into the vitreous (i.e., via intravitreal injection), for example, in the form of an opthalmologic solution.
- Active principles can be administered to the eye (for example, by application to the outside surface of the eye and/or by intraocular injection) using a delivery device which provides a controlled release of active principle(s) on the surface of the eye or into the eye.
- Said device can be, for example, placed in the lower cul de sac or conjunctival cul-de-sac, below the cornea, or injected into the eye, especially into the vitreous.
- logical form it is meant herein a form appropriate for topical administration, and especially a solution (in particular, an ophthalmologic solution), a lotion, drops (in particular, eye drops), a cream or an ointment.
- pharmaceutically acceptable vehicle encompasses an ophthalmologically acceptable vehicle (or carrier).
- ophthalmologically acceptable vehicle means any vehicle that has substantially no long term or permanent detrimental effect on the eye to which it is administered, in particular, any vehicle that can be placed in the eye and that does not cause eye irritation.
- Opthamologically acceptable vehicles include water (distilled or deionized water), saline solutions, phosphate buffered saline solutions, physiological serum, and other aqueous media.
- adrenergic agent encompasses an alpha adrenergic agonist agent, a derivative of an alpha adrenergic agonist agent, a beta-blocking agent, a derivative of a beta-blocking agents and mixtures thereof.
- an “alpha adrenergic agonist agent” is a drug which has effects similar to, or the same as, epinephrine (adrenaline) or which is susceptible to epinephrine, or similar substances, such as biological receptors. This term includes alpha 1 agonists, and alpha 2 agonists. Alpha 1 agonists stimulate phospholipase C activity in a human and an animal body, which results in vasoconstriction and mydriasis (excessive dilation of the pupil).
- Alpha 2 agonists are able to inhibit adenyl cyclase activity in a human and an animal body and are used notably as antihypertensives, sedatives, to reduce eye's aqueous humor secretions and to facilitate aqueous humor outflow via the uveoscleral route.
- alpha 1 agonist include neosynephrine.
- alpha 2 agonists include brimonidine, aprachlonidine and clonidine.
- alpha adrenergic agonist agents that can be used in the present methods and compounds of the present invention include methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, neosynephrine pivalat, beta-methylepinephrine, guanfacine, guanabenz, guanoxabenz, guanethidine, tizanidine, and mixtures thereof.
- an alpha adrenergic agonist agent a compound obtained via a chemical modification of an alpha 1 agonist or an alpha 2 agonist, and which retains respectively the ability to stimulate phospholipase C activity or the ability to inhibit adenyl cyclase activity in an animal model such as a mouse, a rat or a monkey.
- Said derivatives are preferably amine-containing compounds, which more preferably have pKa's of greater than 7, preferably about 7.5 to 9.
- the alpha 1 or alpha 2 activity of a derivative of an adrenergic agonist agent can be shown, for example, by applying to one eye of a mouse, a rat or a monkey, few drops (one, two or three) of said derivative in solution in an ophthalmologically acceptable carrier, and applying, to the other eye of the same animal, the same volume of the ophthalmologically acceptable carrier alone, and comparing dilation of the pupil (in the case of an alpha 1 agonist derivative) or aqueous humor secretions (in the case of an alpha 2 agonist derivative) of both eyes.
- “Derivatives of an alpha adrenergic agonist agent” include imidazoline derivatives such as oxymetazoline, xylometazoline, tetrahydrozoline and the like. Also those derivatives defined in U.S. Pat. Nos. 7,345,077 and 7,335,803 can also be used as derivatives in the methods, compositions and kits of the present invention.
- beta-blocking agent or beta-adrenergic antagonist agent
- a drug which blocks the action of epinephrine (adrenaline) and/or norepinephrine (noradrenaline) in a human and an animal body. These compounds are used notably to lower intraocular tension and/or to reduce eye's aqueous humor secretions. This term encompasses antagonists of the beta 1, beta 2 and beta 3adrenergic receptors.
- beta-blocking agents that can be used in the methods, the compositions and the kits of the present invention include timolol, sotalol, propranolol, penbutolol, nadolol, metoprolol, labetalol, esmolol, carteolol, bisoprolol, betaxolol atenolol, acebutolol, levobunolol, metipranolol and mixtures thereof.
- Beta-blocking agent derivative it is meant a compound obtained via a chemical modification of a beta-blocking agent as defined above, and which retains the ability to lower intraocular tension and/or to reduce eye's aqueous humor secretions in an animal model such as a mouse, a rat or a monkey. These properties can be shown, for example, by applying, to one eye of a mouse, a rat or a monkey, few drops (one, two or three) of said derivative in solution in an ophthalmologically acceptable carrier, and applying, to the other eye of the same animal, the same volume of the ophthalmologically acceptable carrier alone, and measuring and comparing intraocular tension and/or aqueous humor secretions of both eyes.
- Beta-blocking agent derivatives include guaiacoxy propanolamine derivatives such as those described in U.S. Pat. No. 5,804,603.
- the invention relates to a composition, in particular, to a pharmaceutical composition (or drug, or medicament), characterised in that it comprises, consists essentially of, or consists of several (i.e., two or more than two) active principles chosen among an angiotensin-converting enzyme inhibitor (also called ACE inhibitor or ACEI herein), folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, a pharmaceutically acceptable salt thereof or a derivative thereof, and mixtures thereof.
- an angiotensin-converting enzyme inhibitor also called ACE inhibitor or ACEI herein
- composition of the invention further comprises a pharmaceutically acceptable vehicle, and, in particular, one or several ophthalmologically acceptable vehicle(s).
- a pharmaceutically acceptable vehicle and, in particular, one or several ophthalmologically acceptable vehicle(s).
- the composition of the invention comprises, consists essentially of or consists of: (i) a combination of active principles as disclosed herein, and one or several pharmaceutically acceptable vehicle(s), especially one or several ophthalmologically acceptable vehicle(s), which can be as disclosed herein.
- the composition comprises, consists essentially of, or consists of several active principles chosen among an ACEI, folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- active principles chosen among an ACEI, folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- Composition 1 is a composition of Composition 1:
- composition of the invention which is called herein composition 1, comprises, consists essentially of, or consists of:
- the ACEI as used herein is an inhibitor for the enzyme converting angiotensin I to angiotensin II.
- the ACEI is more lipophilic in nature than Enalaprilat.
- the ACEI comprises, consists essentially of, or consists of Ramipril, Ramiprilat, one of their pharmaceutically acceptable salts, or a derivative of Ramipril or Ramiprilat that can liberate Ramipril or Ramiprilat into the animal to which the active principle is administered, or a mixture thereof.
- the ACEI comprises, consists essentially of, or consists of Ramipril.
- the second active principle of composition 1 comprises, consists essentially of, or consists of folic acid, folate, one of their pharmaceutically acceptable salts or a derivative thereof, or a mixture thereof.
- the second active principle of composition 1 comprises, consists essentially of, or consists of folic acid.
- the first active principle is ramipril and/or ramiprilate and the second active principle is folic acid and/or folate or a mixture of (i) folic acid and/or folate and (ii) magnesium or a pharmaceutically acceptable salt thereof and/or potassium or a pharmaceutical acceptable salt thereof.
- composition 1 of the invention comprises, consists essentially of or consists of:
- the second active principle of composition 1 comprises, consists essentially of, or consists of:
- composition 1 can, for example, comprise, consist essentially of, or consist of the following agents: folic acid, magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, and a leucine as disclosed herein, for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine.
- the pharmaceutically acceptable potassium salt as used herein is potassium chloride.
- the pharmaceutically acceptable magnesium salt as used herein is magnesium chloride.
- leucine it is meant herein acetyl-leucine, for example, N-acetyl-leucine, and more especially acetyl-L-leucine (especially N-acetyl-L-leucine), acetyl-D-leucine (especially N-acetyl-D-leucine) or, more preferably, acetyl-DL-leucine (especially the N-acetyl-DL-leucine).
- the N-acetyl-DL-leucine is marketed by Pierre Fabre Medicament as an anti-vertigo medicament under the name Tanganil.
- a DL leucine can also be used as “leucine” according to the invention.
- the third active principle of composition 1 comprises or consists of L-arginine or H4b or vitamin B6 or vitamin B12 or vitamin C or a w-3 fatty acid or an anti-inflammatory agent (for example, indomethacin or dexamethasone) or a beta-blocking agent (for example timolol) or adrenaline or noradrenaline or an alpha adrenergic agonist agent (for example, neosynephrine, brimonidine, aprachlonidine or clonidine or mixtures thereof, in particular brimonidine) or an anti-VEGF (for example, bevacizumab, ranibizumab or pegaptanib).
- an anti-inflammatory agent for example, indomethacin or dexamethasone
- a beta-blocking agent for example timolol
- adrenaline or noradrenaline or an alpha adrenergic agonist agent for example, neosynep
- the third active principle of composition 1 comprises, consists essentially of, or consists of a mixture of compounds as set forth in Table 1.
- This third active principle can be used according to the invention in combination, for example, with (i) Ramipril (or Ramiprilate) and (ii) folic acid (or folate) and/or Magnesium (or a magnesium salt) and/or potassium (or a potassium salt and/or a leucine as disclosed herein and/or glucose.
- w-3 fatty acids can be used according to the invention, and, in particular, a ⁇ -linolenic acid (ALA), a eicosapentaenoic acid (EPA), or a docosahexaenoic acid (DHA).
- ALA ⁇ -linolenic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- the alpha adrenergic agonist agents that can be used in the composition, a medicament, the kit and the methods of the invention can be selected from the group comprising or consisting of methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, neosynephrine, in particular, neosynephrine pivalat, beta-methylepinephrine, brimonidine, apraclonidine, clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, tizanidine, and mixtures thereof.
- the alpha adrenergic agonist agent can be neosynephrine, brimonidine, aprachlonidine or clonidine or mixtures thereof, for example brimonidine (Alphagan®), which can be used, for example, in an amount of 0.2% (w/v).
- the beta-blocking agents that can be used in the composition, a medicament, the kit and the methods of the invention can be selected from the group comprising or consisting of timolol, sotalol, propranolol, penbutolol, nadolol, metoprolol, labetalol, esmolol, carteolol, bisoprolol, betaxolol, bisoprolol, atenolol, acebutolol, levobunolol, metipranolol and mixtures thereof.
- the beta-blocking agent can be timolol, which can be used, for example, in an amount of 0.5% (w/v).
- anti-inflammatory agents examples include non-steroidal anti-inflammatory agents or steroidal anti-inflammatory agents, in particular, corticosteroids, or mixtures thereof.
- Non-steroidal anti-inflammatory drugs can be selected, for example, among aspirin, arylalkanoic acids, in particular, bromfenac, indometacin, oxameticin, 2-arylpropionic acids, in particular, fenbufen, pirprofen, ketoprofen, ibuprofen, oxaprozin, and ketorolac, femamic acids, pyrazolone derivatives, in particular, clofezonem kebuzone and phenazone, ocicams, in particular, droxicam and meloxicam, and COX-2 inhibitors, in particular, celecoxib and rofecoxib.
- the non steroidal anti-inflammatory agent can be indomethacin (Indocollyre®), which can be used, for example, in an amount of 0.1% (w/v).
- corticosteroids examples include cortisone, hydrocortisone, deltacortisone or prednisolone, prednisone, deltahydrocortisone or prednisolone, methylprednisolone or medrocortisone, fluorohydrocortisone or fluorocortisone, fluoromethylprednisolone or dexamethazone, fluoromethyldeltahydrocortisone or betamethazone and paramethazone.
- the corticosteroid can be dexamethasone (Tobradex®); which can be used, for example, in an amount of 0.1% (w/v).
- B6 and/or B12 and/or C it is mean vitamin B6 or vitamin B12 or vitamin C or vitamin B6 and vitamin B12 or vitamin B6 and vitamin C or vitamin B12 and vitamin C or vitamin B6 and vitamin B12 and vitamin C.
- beta-blocking and/or alpha adrenergic agonist it is meant a beta-blocking agent (for example timolol) or an alpha adrenergic agonist agent (for example, brimonidine) or a beta-blocking agent and an alpha adrenergic agonist agent (for example, timolol and brimonidine)
- adrenaline and/or noradrenaline it is meant adrenaline or noradrenaline or adrenaline and noradrenaline.
- the anti-inflammatory agents can be indomethacin or dexamethasone.
- the anti-VEGF agents can be bevacizumab, ranibizumab or pegaptanib.
- Anti-VEGF agents that can be used in the methods, the compositions and the kits of the present invention can be selected among bevacizumab (Avastin®), ranibizumab (Lucentis®), pegaptanib (Macugen®), and mixtures thereof.
- the Anti-VEGF agent can be bevacizumab or ranibizumab.
- Composition 2 is a composition of Composition 2:
- composition of the invention which is called herein composition 2, comprises, consists essentially of, or consists of:
- the first active principle of composition 2 comprises, consists essentially of, or consists of folic acid and/or folate.
- the second active principle of composition 2 comprises, consists essentially of, or consists of:
- composition 2 in composition 2:
- composition 2 in composition 2:
- Composition 3 is a composition of Composition 3:
- composition of the invention which is called herein composition 3, comprises, consists essentially of, or consists of:
- composition 3 comprises, consists essentially of, or consists of:
- the third active principle of composition 3further comprises L-arginine.
- the composition of the invention (for example, composition 1, 2 or 3) is a cellprotector and/or a neuroprotector and/or a retinoprotector.
- a composition or a medicament according to the invention is suitable for preventing, slowing down or interrupting the visual function degradation process or even reversing its course in an animal (especially a human or non human mammal) and, in particular, in an aging animal and/or in an animal with an eye condition (especially an eye disease or disorder).
- said composition is suitable for maintaining or improving visual acuity and/or field of vision in an animal (especially a human or non human mammal) and, in particular, in an aging animal and/or in an animal with an eye condition (especially an eye disease or disorder).
- Said composition can also be applied to a normal subject (i.e. to an animal which does not have any apparent eye disease or disorder), for maintaining eye vision (i.e., for preventing a loss of vision) or even for improving visual acuity and/or visual field.
- composition or medicament according to the invention can be in a form appropriate for (and, in particular, can comprise a vehicle appropriate for) enteral (for example, oral), parenteral (for example, intravenous, intramuscular or subcutaneous), transdermal, or local or topical administration, and especially topical administration to the eye.
- enteral for example, oral
- parenteral for example, intravenous, intramuscular or subcutaneous
- transdermal or local or topical administration
- topical administration to the eye and especially topical administration to the eye.
- forms appropriate for administration to the eye include the ones which are appropriate for application to the outside surface of the eye, for intraocular administration (or injection), especially intravitreal injection and/or for sub-tenonian administration.
- the composition of the invention (for example, composition 1, 2 or 3 as disclosed herein) is in the form of a tablet, a solution (for example, an ophthalmic solution), a lotion, drops (for example, eye drops), a cream or an ointment.
- the composition of the invention (for example, composition 1, 2 or 3 as disclosed herein) is in the form of an ophthalmic solution, an eye ointment or eye drops, such a composition being obtainable, for example, by diluting the active principles in an opthamologically acceptable vehicle, for example, in a physiological serum.
- the composition of the invention (for example, composition 1 as disclosed herein) is an ophthalmic solution or eye drops which comprises, consists essentially of, or consists of ramipril and folic acid.
- the composition of the invention is an ophthalmic solution or eye drops which comprises, consists essentially of, or consists of folic acid, magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, a leucine as disclosed herein (for example, the N-acetyl-DL-leucine), and optionally L-arginine.
- the composition of the invention is an ophthalmic solution or eye drops, which comprises, consists essentially of, or consists of glucose, magnesium (or one of its pharmaceutically acceptable salts), potassium (or one of its pharmaceutically acceptable salts) and a leucine as disclosed herein (for example, the N-acetyl-DL-leucine), and optionally L-arginine.
- the invention relates to a composition as disclosed herein, for use as a medicament in particular, this composition can be used as a cellprotector, a neuroprotector and/or a retinoprotector medicament.
- the composition of the invention is for use in the prevention or the treatment of any one or several disease(s) or disorder(s) chosen from: ophthalmologic conditions (especially ophthalmologic diseases and disorders as disclosed herein), cancers (for example, carcinoma, and more especially adeno-carcinoma), arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infection).
- ophthalmologic conditions especially ophthalmologic diseases and disorders as disclosed herein
- cancers for example, carcinoma, and more especially adeno-carcinoma
- arterial hypertension for example, hyperlipemia, coronary heart disease, atherosclerosis, diabete
- neurodegenerative conditions for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease
- rheumatism general inflammatory and immune conditions and infections (for example
- the composition of the invention is for use in the prevention or the treatment of one or several ophthalmologic condition(s) as disclosed herein and, in particular, of one or several ophthalmologic condition(s) chosen from: glaucoma neuropathy, glaucoma, myopia, presbyopia, ammetropia, hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's disease, ARMD, diabetic retinopathy and keratoconjunctivitis caused by dry eye syndrome.
- ophthalmologic condition(s) chosen from: glaucoma neuropathy, glaucoma, myopia, presbyopia, ammetropia, hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's disease, ARMD, diabetic retinopathy and keratoconjunctivitis caused by dry eye syndrome.
- the ophthalmologic condition is an hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's disease
- the treated patients are under the age of forty, preferably under the age of thirty, and more preferably under the age of twenty, for example, from 6 to 30 or from 6 to 20 years of age.
- the composition, a medicament, the kit and the methods according to the invention are intended for or used to prevent, slow down, stop or even reverse (at least partially) a loss of vision and especially a loss of visual acuity and/or field of vision, said loss of vision resulting, for example, from a natural visual decline and/or from an ophthalmologic disorder or disease as disclosed herein.
- the composition, a medicament, the kit and the methods according to the invention are intended for or used for maintaining or improving (i.e., increasing) eye vision (in particular, visual acuity and/or visual field), for example, in a normal subject (i.e. in an animal which does net have any apparent eye disease or disorder) and/or in an aging animal (especially an aging human or non human mammal) and/or in an animal having a ophthalmologic condition as disclosed herein.
- eye vision in particular, visual acuity and/or visual field
- composition, a medicament, the kit and the methods according to the invention can, in particular, be intended for or used for maintaining or improving vision of one or both eyes, and more particularly for improving distance vision and/or near vision of one or both eyes in a normal animal and/or in an aging animal (especially an aging human or non human mammal) and/or in an animal having a ophthalmologic condition as disclosed herein.
- the invention concerns a cellprotective, neuroprotective and retinoprotective composition
- a cellprotective, neuroprotective and retinoprotective composition comprising or consisting of angiotensin converting enzyme inhibitor (for example, Ramipril or Ramiprilate) associated with folic acid, with or without magnesium, with or without potassium, with or without vitamin B6, with or without vitamin B12, with or without vitamin C, with or without L-arginine, with or without w-3 fatty acids, with or without H4B, with or without glucose, and with or without amino-acids (for example, with or without a leucine, especially an acetyl-leucine, and more especially the N-acetyl-DL-leucine), which composition is sufficiently stable not only to interrupt the visual function degradation process in an animal (especially a patient) suffering from an ophthalmologic condition (especially a ophthalmologic disorder or disease) as disclosed herein, but also to reverse or regress that process.
- the invention concerns the use of the active principles described herein for the manufacture of a composition, a medicament or a kit (as disclosed hereinafter) intended for use in inducing an improvement in visual acuity and field of vision in a treated animal (especially a human or non human mammal).
- the invention also relates to a composition or a kit as disclosed herein, for the manufacture of medicament and, in particular, a cellprotector, a neuroprotector and/or a retinoprotector medicament, said medicament being intended for use in the prevention or the treatment of one or several disease(s) or disorder(s) as disclosed herein, and, for example, of one or several ophthalmologic conditions as disclosed herein, in an animal (especially a human or non human mammal).
- the manufactured composition or medicament is in the form of a tablet, a solution (for example, an ophthalmic solution), an ointment, a lotion, drops (for example, eye drops), an ointment or a cream.
- a solution for example, an ophthalmic solution
- an ointment for example, a lotion
- drops for example, eye drops
- an ointment or a cream for example, a cream.
- the composition or medicament and the kit of the invention are appropriate for caring out a method as disclosed herein.
- the invention also relates to a kit which comprises or consists of:
- the kit comprises or consists of:
- composition 1, 2 or 3 are in the form of one single composition, i.e., that the kit comprises a composition of the invention (for example, composition 1, 2 or 3).
- kit of the invention comprises at least two or three separate compositions, each of these compositions comprising, consisting essentially of, or consisting of one or several active principle(s) (and a pharmaceutically acceptable vehicle, especially an ophthalmologically acceptable vehicle).
- the first active principle, the second active principle or the third active principle which is used in the kit or the methods of the invention comprises a mixture of several active principles
- these active principles can be present in the same composition or alternatively at least two of these active principles can be in separate compositions.
- compositions which can be present in the kit of the invention can be administered either simultaneously or not (in any order) to an animal (especially an aging human or non human mammal), for example, to carry out a method of the invention.
- the active principles present in the kit and, in particular, the first, the second and—if present—the third active principle present in the kit of the invention are associated with pharmaceutically acceptable vehicles allowing their administration, in different forms, in particular: enteral forms especially oral forms, parenteral forms, for example, intravenous forms or intramuscular forms, transdermal forms, and topical forms, in particular, topical forms appropriate for administration to the eye, including the topical forms appropriate for application to the outside surface of the eye, for intraocular or intravitreal injection and/or for sub-tenonian administration (for example, eye or ophthalmic solutions or eye drops).
- enteral forms especially oral forms
- parenteral forms for example, intravenous forms or intramuscular forms, transdermal forms
- topical forms in particular, topical forms appropriate for administration to the eye, including the topical forms appropriate for application to the outside surface of the eye, for intraocular or intravitreal injection and/or for sub-tenonian administration (for example, eye or ophthalmic solutions or eye drops).
- the dosage of each of the active principles present in a composition, a medicament or a kit according to the invention can vary from one patient to another and fine tuning can be left to the clinician.
- a composition, a medicament or a kit according to the invention are intended for treating of preventing a loss of vision and especially for treating of preventing eye conditions as disclosed herein, there is clear preference for topic forms of administration, in particular, eye or ophthalmic solutions or eye drops, in other words, in the preferred administration forms of a composition or medicament according to the invention or of the active principles present in the kit of the invention, the combined active principles used are associated with pharmaceutical vehicles that allow their clinical application in the form of eye lotions, eye ointment, eye solutions, or eye drops, preferably eye solutions or eye drops.
- At least two of the active principles of the kit are in separate compositions, and at least one of these separate compositions is formulated in a topical form appropriate for administration to the eye, for example, a form appropriate for contacting the eye with active principles as disclosed herein (especially eye drops or an eye solution) and/or for intraocular or intravitreal injection and/or is used for administration to the eye (for example, by contacting the eye with active principles as disclosed herein or via intraocular or intravitreal injection).
- the other separate composition(s) can be formulated either in a topical form appropriate for administration to the eye (for example, eye drops or an eye solution) or in another administration form, for example, in an oral form.
- any form of administration can be used, for example, any form appropriate for oral or parenteral administration.
- the invention relates to a method of preventing and/or treating one or several disease(s) or disorder(s) (in particular, one or several eye condition(s) as disclosed herein) in an animal (especially a human or non human mammal) in need thereof, said method comprising (or consisting in) administering to said animal at least two active principles as defined herein and, in particular, a first active principle, a second active principle and optionally a third active principle as defined herein for composition 1, 2 or 3 (or compositions) or medicament(s) comprising them), wherein said active principles are administered separately (i.e., in separate compositions) or not separately (for example, in the same composition), and wherein said disease(s) or disorder(s) is(are), for example, as defined herein.
- the invention in another aspect, relates to a method for maintaining or improving vision and, in particular, the visual acuity and/or the field of vision in an animal (especially a human or non human mammal) in need thereof, said method comprising (or consisting in) administering to said animal at least two active principles as defined herein and, in particular, a first active principle, a second active principle and optionally a third active principle as disclosed herein for composition 1, 2 or 3 (or composition(s) or medicament(s) comprising them), wherein said active principles are administered separately (i.e., in separate compositions) or not separately.
- administered separately or not if is meant herein administered in the form of separate compositions or not.
- not administered separately if is meant herein that at least two of these active principles are in separate compositions (as disclosed herein for the kit of the invention). These separate compositions can be administered simultaneously or not to the animal.
- the methods of the invention can be performed using the kit of the invention.
- the methods of the invention can comprise or consist in administering to an animal (especially a human or non human mammal) in need thereof a composition of the invention (for example, composition 1, 2 or 3).
- composition(s) comprising active principles for example, the first active principle and/or the second active principle and/or the third active principle as disclosed herein for composition 1, 2 or 3 which is(are) administered according to a method of the invention is(are) cellprotector, neuroprotector and/or retinoprotector composition(s).
- administering it is meant herein applying active principles (for example, the first, the second and/or the third active principle as disclosed herein) and, in particular, the composition of the invention to the outside surface of one eye or both eyes of an animal (especially a human or non human mammal), and, in particular, contacting the surface of one eye or of both eyes of an animal with said active principles or with a composition of the invention.
- active principles or composition can be, for example, in the form of an ophtalmologic solution, eyedrops or an ointment.
- administering it is meant herein injecting in one eye or both eyes, especially injecting into the vitreous of one eye or of both eyes of an animal (especially a human or non human mammal), active principle(s) (in particular, the first, the second and/or the third active principle as disclosed herein), which active principle(s) can be, for example, in the form of an ophtalmologic solution.
- the active principles and, in particular, the first active principle and/or the second active principle and/or the third active principle (or composition(s) comprising them) can be administered by the same route (for example, the topical route as disclosed herein) or via different routes, which routes can be chosen independently, for example, from the administration routes disclosed herein.
- At least one of these active principles can be in the form of an ophthalmic solution or eye drops or ointment.
- the treated animal especially a human or non human mammal
- the treated animal has one or several ophthalmologic condition(s) as defined herein and/or is aged.
- a composition, a medicament, a kit or a method according to the invention is intended for or applied to a human being (or patient).
- aged or “aging” it is meant, for example, above the age of 50, above the age of 60 or above the age of 70.
- Effective amounts and/or pharmaceutically acceptable amounts (especially physiologically or ophtalmologically acceptable amounts) of active principles, and especially of the first active principle, the second active principle and—if any—the third active principle are used.
- an active principle is usually administered to a human or an animal in order to prevent or treat an eye condition in a concentration ranging from 0.001 to 15% (w/v), preferably from 0.05 to 10% (w/v), and more preferably from 0.1 to 3% (w/v).
- an active principle in the form of eye drops can be used, for example, in a concentration ranging from 0.1 to 5 % and more preferably from 0.5 to 3%, for example, in a concentration of 0.5%, 1% or 2%.
- Ramipril or Ramiprilate can be administered to a human:
- Folic acid or folate can be administered to a human
- compositions or medicaments that contain the active principles as defined herein may be administered to a mammalian eye as often as necessary to obtain an improvement of the disorder or disease (and especially of the ophthalmic condition).
- a mammalian eye as often as necessary to obtain an improvement of the disorder or disease (and especially of the ophthalmic condition).
- the frequency of administration and duration of treatment depends on the precise nature of the active principles and its concentration in the composition, and various factors such as the type and severity of the disorder or disease, the age and weight of the animal, the animal's general physical condition and the cause of the disorder or disease.
- the ophthalmic composition (preferably ophthalmic solutions or eye drops) of the present invention will be administered topically to the mammalian eye and, in particular, dropped into the eye and/or injected into the mammalian eye approximately once, twice or three times daily.
- the duration of treatment administered in accordance with the present invention may range, for example, from a few weeks (at least one week) to a few months (at least one month), in particular, from 1 week to 8 months, preferably at least 2 weeks and less than 4 months and more preferably at least 3 weeks and less than 3 months.
- a prolonged treatment may be required.
- the treatment may last for one or several years or even for life, for example, in case of recurrence of the disorder(s) or disease(s) and especially of an ophthalmic condition.
- one of several additional active principle(s), and especially one of several additional compounds for treating eye disorders and/or diseases may be used in the methods of the invention or may be present in a composition, a medicament or a kit according to the invention, provided that they do not interact with the first and second active principles and—if present—with the third active principle, to provide adverse side effects.
- the invention relates, in particular, to the following embodiments:
- Point 1 A method for maintaining or improving the visual acuity and/or the field of vision in a patient in need of such treatment. Said method comprising: administering a drug combining: Ramipril (angiotensin converting enzyme inhibitor)—folic acid. This drug maintains or improves visual acuity and the field of vision.
- Ramipril angiotensin converting enzyme inhibitor
- Point 2 The method according to point 1, wherein said drug is a cellprotector, a neuroproteetor and/or a retinoprotector.
- Point 2a The method according to point 1, wherein said drug is associated with one or several compounds chosen among L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, magnesium, potassium, glucose, non steroid anti-inflammatory drug, steroidal anti-inflammatory drug, and amino-acids, for example, leucine (especially acetyl-leucine), beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents and anti-VEGF agents.
- leucine especially acetyl-leucine
- beta-blocking agents for example, leucine (especially acetyl-leucine), beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents and anti-VEGF agents.
- Point 3 The method according to point 1, wherein said drug is associated with one or several compounds chosen among L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, magnesium, potassium, glucose, non steroid anti-inflammatory drug, steroidal anti-inflammatory drug, and amino-acids, for example, leucine (especially acetyl-leucine).
- Point 4 The method according to point 1, wherein said drug is administered orally.
- Point 5 The method according to point 1, wherein said drug is administered parenterally.
- Point 8 The method according to point 5, wherein said drug is administered topically to the eye (ophthalmic solution; ointment).
- Point 7 The method according to point 1, wherein said patient has glaucoma or glaucoma neuropathy.
- Point 8 The method according to point 1, wherein said patient has an hereditary dystrophy of the retina, for example, a pigmentary retinopathy or a stargardt's disease,
- Point 9 The method according to point 1, wherein said patient has a diabetic retinopathy.
- Point 10 The method according to point 1, wherein said patient has an age related macular degeneration with or without choroidal new vessels.
- Point 11 The method according to point 1, wherein said patient has an uveitis, papillitis.
- Point 12 The method according to point 1, wherein said patient has an ammetropia, for example, a myopia, a presbyopia or a hypermetropia.
- ammetropia for example, a myopia, a presbyopia or a hypermetropia.
- Point 13 The method according to point 1, wherein said patient has a retinal arterial or vein occlusion.
- Point 14 The method according to point 1, wherein normal subject has a physiologic decreased vision.
- Point 15 The method according to point 1, wherein said patient has corneal disorders and dry eye syndrome and/or keratoconjunctivitis caused by dry eye syndrome.
- Point 16 The method according to point 1, wherein said patient has an ocular allergy (conjunctivitis).
- Point 17 The method according to point 1, wherein said patient has general disorder such as: arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (multiple sclerosis, Alzheimer, Parkinson . . . ), rheumatism, general inflammatory and immune conditions, infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infection) and cancer (for example, carcinoma, especially adeno-carcinoma).
- general disorder such as: arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (multiple sclerosis, Alzheimer, Parkinson . . . ), rheumatism, general inflammatory and immune conditions, infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infection) and cancer (for example, carcinoma, especially adeno-carcinoma).
- the active principles in particular, Ramipril and folic acid ware administered continuously (i.e., at least once a day), in an oral form of 1.26 mg per day for Ramipril and 5 mg per day for folic acid or in a topical form.
- GLAUCOMA AMD GLAUCOMATOUS NEUROPATHY the administration of the combination of Ramipril and folic acid in oral or topic form induces improvement in the visual function (visual acuity or visual field) and decreased intraocular pressure in 18 individuals.
- MYOPIA 3 patients were tested, The patient's vision was tested before and after the first eye-drop formulation was administered. 2 hours later, the patient's unaided distance vision improved. Wearing distance-corrected glasses, the patient vision improved.
- PRESBYOPIA 5 patients were tested. The patient's near vision was tested before treatment. 2 hours after this treatment the patient's near vision increased.
- AMMETROPIA improvement of near and distance vision 2 hours after treatment.
- 1-Retinitis pigmentosa this disorder corresponds to a dystrophy in the cones and rods. It is characterized by the appearance of night blindness in infancy or adolescence, progressive contractions of the peripheral field of vision and results in a substantial loss in visual acuity or even blindness by adulthood. Four patients were treated orally or topically and their visual acuity improved.
- AGE RELATED MACULAR DEGENERATION 12 patients were tested. The majority of patients presenting an age-related macular degeneration with or without sub-retinal neovessels treated with the combination Ramipril and folic-acid experienced improved visual acuity.
- DIABETIC RETINOPATHY All 10 patients were treated with the combination Ramipril and folic acid improved their vision and ocular fundus appearance.
- KERATOCONJUNCTIVITIS BY DRY EYE 2 patients received this treatment and their conditions were improved.
- visual function should be understood to refer more particularly but not in a limiting manner to visual acuity or the field of vision or, as is preferable, to both at once.
- the invention thus concerns, in an embodiment, a cellprotective, neuroprotective and retinoprotective ophthalmologic drug that can interrupt the process of degradation of visual function and even reverse its course.
- the invention is not limited to the use of the Ramipril and folic acid combination for the treatment of the disorders mentioned above.
- the combination of Ramipril and folic acid can also be associated, for example, with one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B, L-arginine, w-3 fatty acids, magnesium, potassium, glucose, and amino-acids (for example, leucine and especially acetyl-leucine).
- CANCER an eighty old woman presented with an adeno-carcinoma (cancer) in the tongue. She received the same treatment (i.e., ramipril and folic acid), which was administered by the oral route and after four months of daily treatment, the volume of the tumour was decreased by about 30%.
- the Increase of NO bioavailability improves endothelial function, significantly reduces endothelial dysfunction, acts against oxidative stress, significantly reduces inflammation, has antithrombotic activity and inhibits blood clot formation.
- Ramipril as an ACEI or Ramiprilat reduces degradation of bradykinin stimulating NO reduction. Long term bradykinin stimulation enhances the release of NO. causing vasodilatation. Ramipril (or Ramiprilat) drastically reduces superoxide production and oxidative stress. But NO formation is critically dependant on the availability of the cofactor H4B which stimulates the conversion of L-arginine to L-citrulline and NO by NOS (NO synthase). Folic acid or folate (vitamin B8) stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and thus enhances the half-life of NO.
- Impaired endothelial NO (eNO) activity is an early marker for cardiovascular disease. Most risk factors for atherosclerosis are associated with impaired endothelium dependent vasodilatation due to reduced NO production. Folate not only reduces plasma homocysteine levels but also enhances eNO synthesis and shows anti-inflammatory actions. It stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and this cellprotective, neuroprotective and retinoprotective ophthalmologic drug that can interrupt the process of degradation of visual function and even reverse its course.
- the invention is not limited to the use of the Ramipril and folic acid combination for the treatment of the disorders mentioned above.
- the combination of Ramipril and folic acid can also be associated, for example, with one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B, L-arginine, w-3 fatty acids, magnesium, potassium, glucose, and amino-acids (for example, leucine and especially acetyl-leucine).
- CANCER an eighty old woman presented with an adeno-carcinoma (cancer) in the tongue. She received the same treatment (i.e., ramipril and folic acid), which was administered by the oral route and after four months of daily treatment, the volume of the tumour was decreased by about 30%.
- the increase of NO bioavailability improves endothelial function, significantly reduces endothelial dysfunction, acts against oxidative stress, significantly reduces inflammation, has antithrombotic activity and inhibits blood clot formation.
- Ramipril as an ACEI or Ramiprilat reduces degradation of bradykinin stimulating NO reduction. Long term bradykinin stimulation enhances the release of NO, causing vasodilatation. Ramipril (or Ramiprilat) drastically reduces superoxide production and oxidative stress. But NO formation is critically dependant on the availability of the cofactor H4B which stimulates the conversion of L-arginine to L-citrulline and NO by HOS (NO synthase). Folic acid or folate (vitamin B9) stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and thus enhances the half-life of NO.
- Impaired endothelial NO (eNO) activity is an early marker for cardiovascular disease. Most risk factors for atherosclerosis are associated with impaired endothelium dependent vasodilatation due to reduced NO production. Folate not only reduces plasma homocysteine levels but also enhances eNO synthesis and shows anti-inflammatory actions. It stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and this enhances the half-life of NO. Vitamin C augments eNO synthesis by increasing intracellular H4B. The ability of folate to augment eNO generation is independent of its capacity to lower plasma homocystein levels.
- the combination of Ramipril and folic acid and, optionally vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, H4B, L-arginine, potassium, magnesium, glucose and/or and amino-acids could be judicious for a novel approach in the prevention and management of various conditions such as eye conditions (as disclosed herein) arterial hypertension, hyperlipidemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (multiple sclerosis, Alzheimer disease, Parkinson disease, etc . . . ), rheumatism, general inflammatory and immune conditions, infections (viral, bacterial and/or parasitic infections), especially HIV infections, and cancer.
Abstract
The invention relates to a cellprotective, neuroprotective and retinoprotective composition. In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid. The composition of the invention can be used, in particular, for the prevention of loss of vision, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies, in particular: glaucoma, diabetic retinopathy, age related macular degeneration, hereditary dystrophy of the retina, uveitis, ammetropia (myopia, presbyopia). This combination of active principles could also be used in general conditions for treating general pathologies (cancer . . . ).
Description
- The invention relates to a composition and, in particular, to a cellprotective, neuroprotective and retinoprotective composition which is especially appropriate for maintaining or improving visual function (visual acuity and/or vision field). In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid.
- The invention also relates to the use of said composition for the prevention or the treatment of different types of disease(s) or disorder(s) and especially of cancers or of ophthalmologic disease(s) or disorders involving chorio-retinal and/or optic nerve, resulting in a progressive loss of vision (visual acuity and/or field of vision).
- Such effects on vision are observed, in particular, in glaucoma, macular degeneration, inherited retinal diseases, myopia, presbyopia, uveitis and diabetic retinopathy.
- In an embodiment of the invention, a combination of angiotensin converting enzyme inhibitor (for example, ramipril or ramiprilate) and folic acid (or folate) and optionally one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B (tetrahydrobiopterin), L-arginine, w-3 fatty acids (omega 3 fatty acids), magnesium, potassium, glucose and/or amino-acids (for example, a leucine, and especially an acetyl-leucine), in appropriate amounts, form a novel approach in the prevention and management of various diseases or disorders and, in particular, of ophthalmologic conditions such as glaucoma, glaucoma neuropathy, age related macular degeneration, inherited retinal dystrophies, myopia, presbyopia, diabetic retinopathy, or other diseases described herein.
- The invention especially aims to provide compositions or medicaments (or drugs) and a kit intended for the prevention and/or the treatment of ophthalmologic diseases or disorders, which can improve visual function, in particular, the field of vision and/or visual acuity in patients suffering from neuropathies such as glaucoma, but also other chorioretinal disorders or deterioration of the optic nerve that may involve a vascular factor. Examples of ophthalmologic diseases that can be mentioned are:
- 1—Glaucomatous neuropathy, including glaucoma itself;
- 2—Degenerative chorio retinopathy;
- 3—Age-related macular degeneration (ARMD);
- 4—Hereditary dystrophies of the retina (including pigmentosa retinopathy and stargardt's maculopathy);
- 5—Retinal vascular occlusion;
- 6—Myopia;
- 7—Presbyopia;
- 8—Uveitis;
- 9—Diabetic retinopathy;
- 10—Corneal disorders, for example, keratoconjunctivitis, dry eye syndrome, or Fuch's corneal dystrophy; and
- 11—Physiologic visual degradation.
- The invention is based, in particular, on the fact that when used to treat patients, Ramipril associated with a second particular active principle, for example, folic acid, causes not only an interruption—which until now has never been observed in patients treated for ophthalmologic diseases and especially diseases of the types mentioned herein—but moreover at least a partial inversion of the process of degradation of visual function, with an improvement in visual acuity and/or field of vision (usually both in visual acuity and field of vision).
- In addition, it was found that folic acid, as well as other particular compounds and especially vitamin c, w-3 fatty acids and H4B augment the activity of Ramipril. Hence, the combination of Ramipril (or ramiprilate) with one or several of these active principles as discloses herein is more efficient to prevent or to treat some ocular pathologies and presents a more cell protective, neuroprotective and retinoprotective effect than each of these drugs used alone.
- The combinations of active principles disclosed herein are not limited to the applications mentioned herein. They can be employed successfully to prevent or stow down or even stop a “natural” decrease in visual acuity, field of vision or both at the same time. In particular, they can be used successfully to prevent and even reverse visual decline in an aging animal (especially an aging human or non human mammal) and especially physiologic visual decline.
- Mean retinal sensitivity reduces linearly with age. This decline starts very early on, from 20 years of age, and accelerates after the age of 60.
- Moreover, it was surprisingly found that the invention can be applied successfully for the treatment of other types of diseases including cancer.
- Ramipril, which is marketed, in particular, as Tritace®, Triatec®, Delix® or Altace®, has the following formula:
- Ramiprilate, which results from de-esterfication of ramipril, has the following formula:
- Folic Acid (also known as vitamin B9, vitamin M or folacin) has the following formula:
- Folate (the naturally occurring form of folic acid) has the following formula:
- The present invention relates to a composition characterised in that it comprises at least two active principles chosen among an angiotensin-converting enzyme inhibitor, folic acid, folate, magnesium, potassium, glucose, amino-acids (especially a leucine and, in particular, an acetyl-leucine), L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof. In an embodiment of the invention, the composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid.
- The composition of the invention can be used as medicament and, in particular, as a cell protector, a neuroprotector and/or a retinoprotector medicament. More especially, this composition is appropriate for use in the prevention and/or the treatment in an animal in need thereof of one or several disease(s) or disorder(s) chosen from: ophthalmologic conditions, cancers, arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infections).
- The invention is also directed to a method of preventing and/or treating one or several disease(s) or disorder(s) in an animal in need thereof, and to a method for maintaining or improving vision and, in particular, the visual acuity and/or the field of vision in an animal in need thereof. Said methods comprise administering to said animal active principles as disclosed herein.
- The invention also relates to a kit appropriate to carry out a method of the invention, and especially to a kit comprising at least two active principles as disclosed herein, and, optionally, instructions for using said kit.
- Unless otherwise indicated, each embodiment disclosed herein is applicable independently of and/or in combination with any one or several of the other described embodiments.
- The term “Vision” or “visual function” as used herein encompasses visual acuity (more especially near and/or far visual acuity) as well as contrast vision, color vision and field of vision (also called visual field herein).
- The term “loss of vision” or “degradation of visual function” as used herein includes partial or total loss of vision, and especially a partial or total loss in visual acuity (near and/or far visual acuity) and/or contrast vision and/or color vision and/or field of vision. It can result from a “natural” visual decline (i.e., it appears in the absence of any apparent eye disease or disorder), for example, in an aging animal, and/or from one or several ophthalmic condition(s) (in particular, an eye disorder and/or an eye disease) as disclosed herein.
- The terms “treating” and “treatment” mean that an ophthalmologic condition (in particular, an eye disorder and/or an eye disease) is improved (at least partially) and, in particular, that the visual acuity and/or the contrast vision and/or the color vision and/or the field of vision of the treated animal is improved, or that the process of degradation of visual function is stopped.
- As used herein, the term “ophthalmologic conditions” (or eye conditions) encompasses ophthalmologic disorders and ophthalmologic diseases involving chorio-retinal and/or optic nerve, resulting in a progressive loss of vision.
- The term “ophthalmologic disorders” (or eye disorders) as used herein encompasses changes in vision, in the appearance of the eye or having abnormal sensations in the eye. Eye disorders include optic nerve disorders and chorio-retinal disorders, as well as trauma such as injuries to the eye, and especially disorders resulting in a progressive visual degradation or loss of vision.
- As used herein, the term “ophthalmologic diseases” (or eye diseases) means any disease of the eye and, in particular, any disease of the eye resulting in a progressive loss of vision. This terminology encompasses the following diseases of the eye:
-
- glaucoma neuropathy or glaucoma;
- macular degeneration and, in particular, ARMD, with or without choroidal new vessels;
- diabetic retinopathy
- degenerative chorio retinopathy:
- hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's maculopathy (or Stargardt's disease);
- retinal arterial occlusions (in particular, central retinal artery occlusion);
- retinal vein occlusion (in particular, central retinal vein occlusion or branch retinal vein occlusion);
- uveitis (in particular, anterior uveitis and/or posterior uveitis);
- papillitis;
- ammetropia, for example, myopia (including high myopia), presbyopia or hypermetropia;
- corneal disorders, for example, keratoconjunctivitis (especially keratoconjunctivitis caused by dry eye syndrome, also called keratoconjunctivitis sicca), dry eye syndrome or Fuch's corneal dystrophy;
- ocular allergy (conjunctivitis);
- age related vision degradation; and
- a natural loss of vision (especially a natural reduction in visual acuity and/or in visual field) and, in particular, physiologic visual decline; and
- night vision decline, and especially hemeralopia.
- The term “animal” as used herein includes mammalians, in particular, humans and non human mammalians, and birds.
- The term “mammalian” or “mammal” as used herein encompasses any of various warm-blooded vertebrate animals of the class Mammalia, including humans and non human mammals, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young.
- By “topical administration” it is meant herein an administration which has a local effect. This term includes especially a sub-tenonian administration, or an administration to the eye (especially on infra- or extra-ocular administration).
- The administration to the eye can be performed, for example, by applying active principle(s) as disclosed herein (which can be, for example, in the form of an ophthalmologic solution, an ointment or eye drops) to the outside surface of the eye, i.e., by contacting the eye and especially the cornea with said active principle(s).
- Alternatively or cumulatively, the administration to the eye can be performed by injecting active principle(s) into the eye and especially into the vitreous (i.e., via intravitreal injection), for example, in the form of an opthalmologic solution.
- Active principles can be administered to the eye (for example, by application to the outside surface of the eye and/or by intraocular injection) using a delivery device which provides a controlled release of active principle(s) on the surface of the eye or into the eye. Said device can be, for example, placed in the lower cul de sac or conjunctival cul-de-sac, below the cornea, or injected into the eye, especially into the vitreous.
- By “logical form”, it is meant herein a form appropriate for topical administration, and especially a solution (in particular, an ophthalmologic solution), a lotion, drops (in particular, eye drops), a cream or an ointment.
- As used herein, the term “pharmaceutically acceptable vehicle” encompasses an ophthalmologically acceptable vehicle (or carrier).
- The term “ophthalmologically acceptable vehicle” as used herein means any vehicle that has substantially no long term or permanent detrimental effect on the eye to which it is administered, in particular, any vehicle that can be placed in the eye and that does not cause eye irritation. Opthamologically acceptable vehicles include water (distilled or deionized water), saline solutions, phosphate buffered saline solutions, physiological serum, and other aqueous media.
- By “consisting essentially of”, it is meant herein that minor ingredients can be added without having a major effect on active principles used in a composition, a medicament, a kit or a method as disclosed herein.
- By “several”, it is meant herein at least two, i.e., two or more than two (for example, three, four, five, six, seven, eight, nine or ten or more than ten).
- The term “adrenergic agent” as used herein encompasses an alpha adrenergic agonist agent, a derivative of an alpha adrenergic agonist agent, a beta-blocking agent, a derivative of a beta-blocking agents and mixtures thereof.
- As used herein, an “alpha adrenergic agonist agent” is a drug which has effects similar to, or the same as, epinephrine (adrenaline) or which is susceptible to epinephrine, or similar substances, such as biological receptors. This term includes alpha 1 agonists, and alpha 2 agonists. Alpha 1 agonists stimulate phospholipase C activity in a human and an animal body, which results in vasoconstriction and mydriasis (excessive dilation of the pupil). Alpha 2 agonists are able to inhibit adenyl cyclase activity in a human and an animal body and are used notably as antihypertensives, sedatives, to reduce eye's aqueous humor secretions and to facilitate aqueous humor outflow via the uveoscleral route. Examples of alpha 1 agonist include neosynephrine. Examples of alpha 2 agonists include brimonidine, aprachlonidine and clonidine. Others alpha adrenergic agonist agents that can be used in the present methods and compounds of the present invention include methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, neosynephrine pivalat, beta-methylepinephrine, guanfacine, guanabenz, guanoxabenz, guanethidine, tizanidine, and mixtures thereof.
- By “derivative of an alpha adrenergic agonist agent”, it is meant a compound obtained via a chemical modification of an alpha 1 agonist or an alpha 2 agonist, and which retains respectively the ability to stimulate phospholipase C activity or the ability to inhibit adenyl cyclase activity in an animal model such as a mouse, a rat or a monkey. Said derivatives are preferably amine-containing compounds, which more preferably have pKa's of greater than 7, preferably about 7.5 to 9. The alpha 1 or alpha 2 activity of a derivative of an adrenergic agonist agent can be shown, for example, by applying to one eye of a mouse, a rat or a monkey, few drops (one, two or three) of said derivative in solution in an ophthalmologically acceptable carrier, and applying, to the other eye of the same animal, the same volume of the ophthalmologically acceptable carrier alone, and comparing dilation of the pupil (in the case of an alpha 1 agonist derivative) or aqueous humor secretions (in the case of an alpha 2 agonist derivative) of both eyes. “Derivatives of an alpha adrenergic agonist agent” include imidazoline derivatives such as oxymetazoline, xylometazoline, tetrahydrozoline and the like. Also those derivatives defined in U.S. Pat. Nos. 7,345,077 and 7,335,803 can also be used as derivatives in the methods, compositions and kits of the present invention.
- By “beta-blocking agent” (or beta-adrenergic antagonist agent) it is meant herein a drug which blocks the action of epinephrine (adrenaline) and/or norepinephrine (noradrenaline) in a human and an animal body. These compounds are used notably to lower intraocular tension and/or to reduce eye's aqueous humor secretions. This term encompasses antagonists of the beta 1, beta 2 and beta 3adrenergic receptors. The beta-blocking agents that can be used in the methods, the compositions and the kits of the present invention include timolol, sotalol, propranolol, penbutolol, nadolol, metoprolol, labetalol, esmolol, carteolol, bisoprolol, betaxolol atenolol, acebutolol, levobunolol, metipranolol and mixtures thereof.
- By “beta-blocking agent derivative”, it is meant a compound obtained via a chemical modification of a beta-blocking agent as defined above, and which retains the ability to lower intraocular tension and/or to reduce eye's aqueous humor secretions in an animal model such as a mouse, a rat or a monkey. These properties can be shown, for example, by applying, to one eye of a mouse, a rat or a monkey, few drops (one, two or three) of said derivative in solution in an ophthalmologically acceptable carrier, and applying, to the other eye of the same animal, the same volume of the ophthalmologically acceptable carrier alone, and measuring and comparing intraocular tension and/or aqueous humor secretions of both eyes. Beta-blocking agent derivatives include guaiacoxy propanolamine derivatives such as those described in U.S. Pat. No. 5,804,603.
- In a first aspect, the invention relates to a composition, in particular, to a pharmaceutical composition (or drug, or medicament), characterised in that it comprises, consists essentially of, or consists of several (i.e., two or more than two) active principles chosen among an angiotensin-converting enzyme inhibitor (also called ACE inhibitor or ACEI herein), folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, a pharmaceutically acceptable salt thereof or a derivative thereof, and mixtures thereof.
- The composition of the invention further comprises a pharmaceutically acceptable vehicle, and, in particular, one or several ophthalmologically acceptable vehicle(s). This means that the composition of the invention comprises, consists essentially of or consists of: (i) a combination of active principles as disclosed herein, and one or several pharmaceutically acceptable vehicle(s), especially one or several ophthalmologically acceptable vehicle(s), which can be as disclosed herein.
- In one embodiment of the invention, the composition comprises, consists essentially of, or consists of several active principles chosen among an ACEI, folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- In one embodiment of the invention, the composition of the invention, which is called herein composition 1, comprises, consists essentially of, or consists of:
-
- a) a first active principle, which comprises, consists essentially of, or consists of an ACEI; and
- b) a second active principle (or a second active principle mixture), which is chosen among:
- folic acid, folate, magnesium, potassium, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), one of their pharmaceutically acceptable salts or derivative thereof, and mixtures thereof; and, in particular, which is chosen among:
- folic acid, folate, glucose, amino-acids (for example, a leucine, especially an acetyl-leucine), one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
- c) optionally, a third active principle, which is chosen among: L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- In an embodiment of the invention, the ACEI as used herein is an inhibitor for the enzyme converting angiotensin I to angiotensin II.
- In an embodiment of the invention, the ACEI is more lipophilic in nature than Enalaprilat.
- In an embodiment of the invention, the ACEI comprises, consists essentially of, or consists of Ramipril, Ramiprilat, one of their pharmaceutically acceptable salts, or a derivative of Ramipril or Ramiprilat that can liberate Ramipril or Ramiprilat into the animal to which the active principle is administered, or a mixture thereof.
- In another embodiment of the invention, the ACEI comprises, consists essentially of, or consists of Ramipril.
- In an embodiment of the invention, the second active principle of composition 1 comprises, consists essentially of, or consists of folic acid, folate, one of their pharmaceutically acceptable salts or a derivative thereof, or a mixture thereof.
- In another embodiment of the invention, the second active principle of composition 1 comprises, consists essentially of, or consists of folic acid.
- In an embodiment of the invention, in composition 1, the first active principle is ramipril and/or ramiprilate and the second active principle is folic acid and/or folate or a mixture of (i) folic acid and/or folate and (ii) magnesium or a pharmaceutically acceptable salt thereof and/or potassium or a pharmaceutical acceptable salt thereof.
- In another embodiment of the invention, composition 1 of the invention comprises, consists essentially of or consists of:
-
- ramipril and folic acid, and
- optionally, magnesium or a pharmaceutical acceptable salt thereof and/or potassium or a pharmaceutically acceptable salt thereof, and
- optionally, a third active principle as disclosed herein and especially a third active principle chosen among L-arginine, H4b, vitamin B6, vitamin B12, vitamin C and w-3 fatty acids.
- In another embodiment of the invention, the second active principle of composition 1 comprises, consists essentially of, or consists of:
-
- folic acid and/or folate, and
- magnesium (or a pharmaceutically acceptable salt thereof) and/or potassium (or a pharmaceutically acceptable salt thereof), and
- glucose and/or amino-acids (in particular, a leucine as disclosed herein), for example glucose and a leucine as disclosed herein).
- Hence, the second active principle of composition 1 can, for example, comprise, consist essentially of, or consist of the following agents: folic acid, magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, and a leucine as disclosed herein, for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine.
- In an embodiment of the invention, the pharmaceutically acceptable potassium salt as used herein is potassium chloride.
- In an embodiment of the invention, the pharmaceutically acceptable magnesium salt as used herein is magnesium chloride.
- In an embodiment of the invention, by “leucine” it is meant herein acetyl-leucine, for example, N-acetyl-leucine, and more especially acetyl-L-leucine (especially N-acetyl-L-leucine), acetyl-D-leucine (especially N-acetyl-D-leucine) or, more preferably, acetyl-DL-leucine (especially the N-acetyl-DL-leucine). The N-acetyl-DL-leucine is marketed by Pierre Fabre Medicament as an anti-vertigo medicament under the name Tanganil. Alternatively, a DL leucine can also be used as “leucine” according to the invention.
- In an embodiment of the invention, the third active principle of composition 1 comprises or consists of L-arginine or H4b or vitamin B6 or vitamin B12 or vitamin C or a w-3 fatty acid or an anti-inflammatory agent (for example, indomethacin or dexamethasone) or a beta-blocking agent (for example timolol) or adrenaline or noradrenaline or an alpha adrenergic agonist agent (for example, neosynephrine, brimonidine, aprachlonidine or clonidine or mixtures thereof, in particular brimonidine) or an anti-VEGF (for example, bevacizumab, ranibizumab or pegaptanib).
- In another embodiment of the invention, the third active principle of composition 1 comprises, consists essentially of, or consists of a mixture of compounds as set forth in Table 1. This third active principle can be used according to the invention in combination, for example, with (i) Ramipril (or Ramiprilate) and (ii) folic acid (or folate) and/or Magnesium (or a magnesium salt) and/or potassium (or a potassium salt and/or a leucine as disclosed herein and/or glucose.
- Any w-3 fatty acids can be used according to the invention, and, in particular, a α-linolenic acid (ALA), a eicosapentaenoic acid (EPA), or a docosahexaenoic acid (DHA).
- The alpha adrenergic agonist agents that can be used in the composition, a medicament, the kit and the methods of the invention can be selected from the group comprising or consisting of methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, neosynephrine, in particular, neosynephrine pivalat, beta-methylepinephrine, brimonidine, apraclonidine, clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, tizanidine, and mixtures thereof. In particular, the alpha adrenergic agonist agent can be neosynephrine, brimonidine, aprachlonidine or clonidine or mixtures thereof, for example brimonidine (Alphagan®), which can be used, for example, in an amount of 0.2% (w/v).
- The beta-blocking agents that can be used in the composition, a medicament, the kit and the methods of the invention can be selected from the group comprising or consisting of timolol, sotalol, propranolol, penbutolol, nadolol, metoprolol, labetalol, esmolol, carteolol, bisoprolol, betaxolol, bisoprolol, atenolol, acebutolol, levobunolol, metipranolol and mixtures thereof. In particular, the beta-blocking agent can be timolol, which can be used, for example, in an amount of 0.5% (w/v).
- Examples of anti-inflammatory agents that can be used according to the invention are non-steroidal anti-inflammatory agents or steroidal anti-inflammatory agents, in particular, corticosteroids, or mixtures thereof.
- Non-steroidal anti-inflammatory drugs can be selected, for example, among aspirin, arylalkanoic acids, in particular, bromfenac, indometacin, oxameticin, 2-arylpropionic acids, in particular, fenbufen, pirprofen, ketoprofen, ibuprofen, oxaprozin, and ketorolac, femamic acids, pyrazolone derivatives, in particular, clofezonem kebuzone and phenazone, ocicams, in particular, droxicam and meloxicam, and COX-2 inhibitors, in particular, celecoxib and rofecoxib. In particular, the non steroidal anti-inflammatory agent can be indomethacin (Indocollyre®), which can be used, for example, in an amount of 0.1% (w/v).
- Examples of corticosteroids that can be used in the composition, a medicament, the kit and the methods of the invention can be selected among cortisone, hydrocortisone, deltacortisone or prednisolone, prednisone, deltahydrocortisone or prednisolone, methylprednisolone or medrocortisone, fluorohydrocortisone or fluorocortisone, fluoromethylprednisolone or dexamethazone, fluoromethyldeltahydrocortisone or betamethazone and paramethazone. In particular, the corticosteroid can be dexamethasone (Tobradex®); which can be used, for example, in an amount of 0.1% (w/v).
-
TABLE 1 Combination of active principles L-arginine x x X X x x x x x x x x x x x x x x x x x x H4b X x X x x X X x x x x x x x x x x w-3 fatty acid(s) X x x x X x x x x x x x x x x x B6 and/or B12 X x x x x x x x x x x x x and/or C anti-inflammatory X agents beta-blocking X and/or alpha adrenergic agonist Adrenaline and/or X x x x x x x x noradrenaline anti-VEGF x x x x x x x x x x x L-arginine x x x x x x x x x x x x x x x x x x x H4b x x x x x x x x x x x x x x w-3 fatty acid(s) x x x x x x x x x x x x x x x B6 and/or B12 x x x x x x x x x x x x x x and/or C anti-inflammatory x x x x x x x x x x x agents beta-blocking x x x x x x x x x x and/or alpha adrenergic agonist Adrenaline and/or x x x noradrenaline anti-VEGF x Examples of active principles that can be used in a composition of the invention, a medicament, the kit and the methods of the invention and, in particular, examples of third active principle that can be used in composition 1 or of active principles that can be included in the second active principle of composition 2 (in combination, for example, with magesium (or a magnesium salt) and/or potassium (or a potassium salt) and/or a leucine (as disclosed herein) and/or glucose. The presence of an active principle in a combination of active principles is indicated by an “x”. By “B6 and/or B12 and/or C”, it is mean vitamin B6 or vitamin B12 or vitamin C or vitamin B6 and vitamin B12 or vitamin B6 and vitamin C or vitamin B12 and vitamin C or vitamin B6 and vitamin B12 and vitamin C. By “beta-blocking and/or alpha adrenergic agonist” it is meant a beta-blocking agent (for example timolol) or an alpha adrenergic agonist agent (for example, brimonidine) or a beta-blocking agent and an alpha adrenergic agonist agent (for example, timolol and brimonidine) By “adrenaline and/or noradrenaline”, it is meant adrenaline or noradrenaline or adrenaline and noradrenaline. The anti-inflammatory agents can be indomethacin or dexamethasone. The anti-VEGF agents can be bevacizumab, ranibizumab or pegaptanib. - Anti-VEGF agents that can be used in the methods, the compositions and the kits of the present invention can be selected among bevacizumab (Avastin®), ranibizumab (Lucentis®), pegaptanib (Macugen®), and mixtures thereof. In particular, the Anti-VEGF agent can be bevacizumab or ranibizumab.
- In another embodiment of the invention, the composition of the invention, which is called herein composition 2, comprises, consists essentially of, or consists of:
-
- (a) a first active principle (or a first active principle mixture), which is chosen among folic acid, folate, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
- b) a second active principle (or a second active principle mixture), which is chosen among: magnesium, potassium, glucose, amino-acids (for example, leucine, especially acetyl-leucine), L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
- c) optionally, a third active principle, which is chosen among: anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- In an embodiment of the invention, the first active principle of composition 2comprises, consists essentially of, or consists of folic acid and/or folate.
- In an embodiment of the invention, the second active principle of composition 2 comprises, consists essentially of, or consists of:
-
- magnesium (or a pharmaceutically acceptable salt thereof) and/or potassium (or a pharmaceutically acceptable salt thereof) and/or glucose and/or amino-acids (for example, leucine, especially acetyl-leucine) and/or L-arginine, and
- optionally, an active principle chosen from H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
- In another embodiment of the invention, in composition 2:
-
- the first active principle comprises, consists essentially of, or consists of folic acid and/or folate; and
- the second active principle comprises, consists essentially of, or consists of:
- (i) magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, and a leucine as disclosed herein, for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine; or
- (ii) magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, a leucine as disclosed herein (for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine) and L-arginine,
- the third active principle being or not being present in said composition.
- In another embodiment of the invention, in composition 2:
-
- the first active principle comprises, consists essentially of, or consists of folic acid and/or folate; and
- the second active principle comprises, consists essentially of, or consists of:
- (i) magnesium (or a pharmaceutically acceptable salt thereof) and/or potassium (or a pharmaceutically acceptable salt thereof) and/or a leucine as disclosed herein and/or glucose; and
- (ii) a mixture of compounds as set forth in Table 1;
- the third active principle being or not being present in said composition.
- In another embodiment of the invention, the composition of the invention, which is called herein composition 3, comprises, consists essentially of, or consists of:
-
- a) a first active principle (or a first active principle mixture), which is chosen among glucose, one of its pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
- b) a second active principle (or a second active principle mixture), which is chosen among: magnesium, potassium, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof, and
- c) a third active principle chosen among amino-acids, for example, a third active principle which comprises or consists of a leucine or a pharmaceutically acceptable salts or a derivative thereof, for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine.
- In an embodiment of the invention, composition 3 comprises, consists essentially of, or consists of:
-
- glucose, as first active principle;
- magnesium (or one of its pharmaceutically acceptable salts) and potassium, (or one of its pharmaceutically acceptable salts) as second active principle; and
- a leucine as disclosed herein, for example, a N-acetyl-leucine and especially the N-acetyl-DL-leucine, as third active principle.
- In an embodiment of the invention, the third active principle of composition 3further comprises L-arginine.
- In an embodiment of the invention, the composition of the invention (for example, composition 1, 2 or 3) is a cellprotector and/or a neuroprotector and/or a retinoprotector.
- In an embodiment of the invention, a composition or a medicament according to the invention is suitable for preventing, slowing down or interrupting the visual function degradation process or even reversing its course in an animal (especially a human or non human mammal) and, in particular, in an aging animal and/or in an animal with an eye condition (especially an eye disease or disorder).
- Hence, in an embodiment of the invention, said composition is suitable for maintaining or improving visual acuity and/or field of vision in an animal (especially a human or non human mammal) and, in particular, in an aging animal and/or in an animal with an eye condition (especially an eye disease or disorder). Said composition can also be applied to a normal subject (i.e. to an animal which does not have any apparent eye disease or disorder), for maintaining eye vision (i.e., for preventing a loss of vision) or even for improving visual acuity and/or visual field.
- The composition or medicament according to the invention can be in a form appropriate for (and, in particular, can comprise a vehicle appropriate for) enteral (for example, oral), parenteral (for example, intravenous, intramuscular or subcutaneous), transdermal, or local or topical administration, and especially topical administration to the eye. Forms appropriate for administration to the eye include the ones which are appropriate for application to the outside surface of the eye, for intraocular administration (or injection), especially intravitreal injection and/or for sub-tenonian administration.
- In one aspect of the invention, the composition of the invention (for example, composition 1, 2 or 3 as disclosed herein) is in the form of a tablet, a solution (for example, an ophthalmic solution), a lotion, drops (for example, eye drops), a cream or an ointment.
- In another aspect of the invention, the composition of the invention (for example, composition 1, 2 or 3 as disclosed herein) is in the form of an ophthalmic solution, an eye ointment or eye drops, such a composition being obtainable, for example, by diluting the active principles in an opthamologically acceptable vehicle, for example, in a physiological serum.
- Hence, in an embodiment of the invention, the composition of the invention, (for example, composition 1 as disclosed herein) is an ophthalmic solution or eye drops which comprises, consists essentially of, or consists of ramipril and folic acid.
- In yet another embodiment of the invention, the composition of the invention (for example, composition 2 as disclosed herein) is an ophthalmic solution or eye drops which comprises, consists essentially of, or consists of folic acid, magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose, a leucine as disclosed herein (for example, the N-acetyl-DL-leucine), and optionally L-arginine.
- In another embodiment of the invention, the composition of the invention (for example, composition 3 as disclosed herein) is an ophthalmic solution or eye drops, which comprises, consists essentially of, or consists of glucose, magnesium (or one of its pharmaceutically acceptable salts), potassium (or one of its pharmaceutically acceptable salts) and a leucine as disclosed herein (for example, the N-acetyl-DL-leucine), and optionally L-arginine.
- In another aspect, the invention relates to a composition as disclosed herein, for use as a medicament in particular, this composition can be used as a cellprotector, a neuroprotector and/or a retinoprotector medicament.
- In an embodiment of the invention, the composition of the invention is for use in the prevention or the treatment of any one or several disease(s) or disorder(s) chosen from: ophthalmologic conditions (especially ophthalmologic diseases and disorders as disclosed herein), cancers (for example, carcinoma, and more especially adeno-carcinoma), arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (for example, multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infection).
- In an embodiment of the invention, the composition of the invention is for use in the prevention or the treatment of one or several ophthalmologic condition(s) as disclosed herein and, in particular, of one or several ophthalmologic condition(s) chosen from: glaucoma neuropathy, glaucoma, myopia, presbyopia, ammetropia, hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's disease, ARMD, diabetic retinopathy and keratoconjunctivitis caused by dry eye syndrome.
- In an embodiment of the invention, the ophthalmologic condition is an hereditary dystrophy of the retina and pigmentary epithelium, for example, pigmentosa retinopathy or Stargardt's disease, and the treated patients are under the age of forty, preferably under the age of thirty, and more preferably under the age of twenty, for example, from 6 to 30 or from 6 to 20 years of age.
- In an embodiment of the invention, the composition, a medicament, the kit and the methods according to the invention are intended for or used to prevent, slow down, stop or even reverse (at least partially) a loss of vision and especially a loss of visual acuity and/or field of vision, said loss of vision resulting, for example, from a natural visual decline and/or from an ophthalmologic disorder or disease as disclosed herein.
- Hence, in an embodiment of the invention, the composition, a medicament, the kit and the methods according to the invention are intended for or used for maintaining or improving (i.e., increasing) eye vision (in particular, visual acuity and/or visual field), for example, in a normal subject (i.e. in an animal which does net have any apparent eye disease or disorder) and/or in an aging animal (especially an aging human or non human mammal) and/or in an animal having a ophthalmologic condition as disclosed herein.
- The composition, a medicament, the kit and the methods according to the invention can, in particular, be intended for or used for maintaining or improving vision of one or both eyes, and more particularly for improving distance vision and/or near vision of one or both eyes in a normal animal and/or in an aging animal (especially an aging human or non human mammal) and/or in an animal having a ophthalmologic condition as disclosed herein.
- In an embodiment, the invention concerns a cellprotective, neuroprotective and retinoprotective composition comprising or consisting of angiotensin converting enzyme inhibitor (for example, Ramipril or Ramiprilate) associated with folic acid, with or without magnesium, with or without potassium, with or without vitamin B6, with or without vitamin B12, with or without vitamin C, with or without L-arginine, with or without w-3 fatty acids, with or without H4B, with or without glucose, and with or without amino-acids (for example, with or without a leucine, especially an acetyl-leucine, and more especially the N-acetyl-DL-leucine), which composition is sufficiently stable not only to interrupt the visual function degradation process in an animal (especially a patient) suffering from an ophthalmologic condition (especially a ophthalmologic disorder or disease) as disclosed herein, but also to reverse or regress that process.
- In another aspect, the invention concerns the use of the active principles described herein for the manufacture of a composition, a medicament or a kit (as disclosed hereinafter) intended for use in inducing an improvement in visual acuity and field of vision in a treated animal (especially a human or non human mammal).
- The invention also relates to a composition or a kit as disclosed herein, for the manufacture of medicament and, in particular, a cellprotector, a neuroprotector and/or a retinoprotector medicament, said medicament being intended for use in the prevention or the treatment of one or several disease(s) or disorder(s) as disclosed herein, and, for example, of one or several ophthalmologic conditions as disclosed herein, in an animal (especially a human or non human mammal).
- In an embodiment of the invention, the manufactured composition or medicament is in the form of a tablet, a solution (for example, an ophthalmic solution), an ointment, a lotion, drops (for example, eye drops), an ointment or a cream. The composition or medicament and the kit of the invention are appropriate for caring out a method as disclosed herein.
- In another aspect, the invention also relates to a kit which comprises or consists of:
-
- several (at least two) active principles chosen among an ACEI, folic acid, folate, magnesium, potassium, glucose, amino-acids (especially a leucine and, in particular, an acetyl-leucine), L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof and mixtures thereof; and
- optionally, instructions for using said kit,
wherein said active principles are associated in the same composition or wherein at least two of these active principles are in separate compositions.
- In an embodiment of the invention, the kit comprises or consists of:
-
- (i) a first active principle; and
- (ii) a second active principle; and
- (iii) optionally, a third active principle; and
- (iv) optionally, instructions for using said kit (for example, in a method of the invention),
wherein the first active principle, the second active principle and—if present—the third active principle are as disclosed herein for composition 1, 2 or 3 and are associated in the same composition or wherein at least two of these active principles are in separate compositions.
- The term “associated in the same composition” (or “present in the same composition”) means that the active principles present in the kit and, in particular, the first active principle, the second active principle and—if present—the third active principle as disclosed herein for composition 1, 2 or 3 are in the form of one single composition, i.e., that the kit comprises a composition of the invention (for example, composition 1, 2 or 3).
- Alternatively, when “at least two of these active principles are in separate compositions”, this means that the kit of the invention comprises at least two or three separate compositions, each of these compositions comprising, consisting essentially of, or consisting of one or several active principle(s) (and a pharmaceutically acceptable vehicle, especially an ophthalmologically acceptable vehicle). For example, a kit which comprises a first active principle, a second active principle and optionally a third active principle as disclosed herein for composition 1, 2 or 3:
-
- may comprise only two separate compositions when:
- (i) the third active principle is not present (in this case, one composition comprises the first active principle and the other composition comprises the second active principle); or
- (ii) the third active principle is present but either the first, the second or the third active principle is separated from the two other active principles in a separate composition; and
- may comprises three separate compositions when the third active principle is present and when each of the three active principles is present in a separate composition (i.e., each of these three compositions comprises, consists essentially of, or consists of one of the three active principles, and a pharmaceutically acceptable vehicle, especially an ophthalmologically acceptable vehicle).
- may comprise only two separate compositions when:
- Or course, when the first active principle, the second active principle or the third active principle which is used in the kit or the methods of the invention comprises a mixture of several active principles, these active principles can be present in the same composition or alternatively at least two of these active principles can be in separate compositions.
- The at least two or three separate compositions which can be present in the kit of the invention can be administered either simultaneously or not (in any order) to an animal (especially an aging human or non human mammal), for example, to carry out a method of the invention.
- In an embodiment of the invention, the active principles present in the kit and, in particular, the first, the second and—if present—the third active principle present in the kit of the invention are associated with pharmaceutically acceptable vehicles allowing their administration, in different forms, in particular: enteral forms especially oral forms, parenteral forms, for example, intravenous forms or intramuscular forms, transdermal forms, and topical forms, in particular, topical forms appropriate for administration to the eye, including the topical forms appropriate for application to the outside surface of the eye, for intraocular or intravitreal injection and/or for sub-tenonian administration (for example, eye or ophthalmic solutions or eye drops). Clearly, the dosage of each of the active principles present in a composition, a medicament or a kit according to the invention can vary from one patient to another and fine tuning can be left to the clinician. When a composition, a medicament or a kit according to the invention are intended for treating of preventing a loss of vision and especially for treating of preventing eye conditions as disclosed herein, there is clear preference for topic forms of administration, in particular, eye or ophthalmic solutions or eye drops, in other words, in the preferred administration forms of a composition or medicament according to the invention or of the active principles present in the kit of the invention, the combined active principles used are associated with pharmaceutical vehicles that allow their clinical application in the form of eye lotions, eye ointment, eye solutions, or eye drops, preferably eye solutions or eye drops.
- In an embodiment of the invention, at least two of the active principles of the kit are in separate compositions, and at least one of these separate compositions is formulated in a topical form appropriate for administration to the eye, for example, a form appropriate for contacting the eye with active principles as disclosed herein (especially eye drops or an eye solution) and/or for intraocular or intravitreal injection and/or is used for administration to the eye (for example, by contacting the eye with active principles as disclosed herein or via intraocular or intravitreal injection). In this case, the other separate composition(s) can be formulated either in a topical form appropriate for administration to the eye (for example, eye drops or an eye solution) or in another administration form, for example, in an oral form.
- When the composition, a medicament or a kit according to the invention are intended for and/or is used for treating other types of diseases, and especially a cancer, any form of administration can be used, for example, any form appropriate for oral or parenteral administration.
- In a further aspect, the invention relates to a method of preventing and/or treating one or several disease(s) or disorder(s) (in particular, one or several eye condition(s) as disclosed herein) in an animal (especially a human or non human mammal) in need thereof, said method comprising (or consisting in) administering to said animal at least two active principles as defined herein and, in particular, a first active principle, a second active principle and optionally a third active principle as defined herein for composition 1, 2 or 3 (or compositions) or medicament(s) comprising them), wherein said active principles are administered separately (i.e., in separate compositions) or not separately (for example, in the same composition), and wherein said disease(s) or disorder(s) is(are), for example, as defined herein.
- In another aspect, the invention relates to a method for maintaining or improving vision and, in particular, the visual acuity and/or the field of vision in an animal (especially a human or non human mammal) in need thereof, said method comprising (or consisting in) administering to said animal at least two active principles as defined herein and, in particular, a first active principle, a second active principle and optionally a third active principle as disclosed herein for composition 1, 2 or 3 (or composition(s) or medicament(s) comprising them), wherein said active principles are administered separately (i.e., in separate compositions) or not separately.
- By “administered separately or not”, if is meant herein administered in the form of separate compositions or not. Hence, when they are administered “separately”, this means that at least two or three separate compositions are used: in particular, when a first active principle, a second active principle and optionally a third active principle as disclosed herein are administered, at least two separate compositions are used when there is no third active principle and at least three separate compositions are used when a third active principle is used. By “not administered separately”, if is meant herein that at least two of these active principles are in separate compositions (as disclosed herein for the kit of the invention). These separate compositions can be administered simultaneously or not to the animal.
- The methods of the invention can be performed using the kit of the invention.
- Cumulatively or alternatively, the methods of the invention can comprise or consist in administering to an animal (especially a human or non human mammal) in need thereof a composition of the invention (for example, composition 1, 2 or 3).
- In an embodiment of the invention, the composition(s) comprising active principles (for example, the first active principle and/or the second active principle and/or the third active principle as disclosed herein for composition 1, 2 or 3) which is(are) administered according to a method of the invention is(are) cellprotector, neuroprotector and/or retinoprotector composition(s).
- In an embodiment of the invention, by “administering” it is meant herein applying active principles (for example, the first, the second and/or the third active principle as disclosed herein) and, in particular, the composition of the invention to the outside surface of one eye or both eyes of an animal (especially a human or non human mammal), and, in particular, contacting the surface of one eye or of both eyes of an animal with said active principles or with a composition of the invention. The administered active principles or composition can be, for example, in the form of an ophtalmologic solution, eyedrops or an ointment.
- Alternatively or cumulatively, in an embodiment of the invention, by “administering” it is meant herein injecting in one eye or both eyes, especially injecting into the vitreous of one eye or of both eyes of an animal (especially a human or non human mammal), active principle(s) (in particular, the first, the second and/or the third active principle as disclosed herein), which active principle(s) can be, for example, in the form of an ophtalmologic solution.
- The active principles and, in particular, the first active principle and/or the second active principle and/or the third active principle (or composition(s) comprising them) can be administered by the same route (for example, the topical route as disclosed herein) or via different routes, which routes can be chosen independently, for example, from the administration routes disclosed herein.
- At least one of these active principles can be in the form of an ophthalmic solution or eye drops or ointment.
- In one aspect of the methods of the invention (especially the method for maintaining or improving vision according to the invention), the treated animal (especially a human or non human mammal) has one or several ophthalmologic condition(s) as defined herein and/or is aged.
- In an embodiment of the invention, a composition, a medicament, a kit or a method according to the invention is intended for or applied to a human being (or patient). In this embodiment, by “aged” or “aging” it is meant, for example, above the age of 50, above the age of 60 or above the age of 70.
- Effective amounts and/or pharmaceutically acceptable amounts (especially physiologically or ophtalmologically acceptable amounts) of active principles, and especially of the first active principle, the second active principle and—if any—the third active principle are used.
- As a way of illustration, an active principle is usually administered to a human or an animal in order to prevent or treat an eye condition in a concentration ranging from 0.001 to 15% (w/v), preferably from 0.05 to 10% (w/v), and more preferably from 0.1 to 3% (w/v). In particular, an active principle in the form of eye drops can be used, for example, in a concentration ranging from 0.1 to 5 % and more preferably from 0.5 to 3%, for example, in a concentration of 0.5%, 1% or 2%.
- Especially Ramipril or Ramiprilate can be administered to a human:
-
- topically (for example, in the form of eye drops) in a concentration of 0.5 to 5% or 0.5 to 3%, for example, in a concentration of 0.5%, 1% or 2%; and/or
- orally in an amount of 0.5 to 5 mg/day, preferably 1 to 2 mg/day, for example, 1.25 mg/day; and
- Folic acid or folate can be administered to a human,
-
- topically (for example, in the form of eye drops) in a concentration of 0.5 to 5% or 0.5 to 3%, for example, in a concentration of 0.5%, 1% or 2%; and/or
- orally, in an amount of 2 to 8 mg/day, preferably 4 to 8 mg/day, for example, 5 mg/day.
- The compositions or medicaments that contain the active principles as defined herein may be administered to a mammalian eye as often as necessary to obtain an improvement of the disorder or disease (and especially of the ophthalmic condition). Those skilled in the art will recognize that the frequency of administration and duration of treatment depends on the precise nature of the active principles and its concentration in the composition, and various factors such as the type and severity of the disorder or disease, the age and weight of the animal, the animal's general physical condition and the cause of the disorder or disease. Within these guidelines, it is contemplated that the ophthalmic composition (preferably ophthalmic solutions or eye drops) of the present invention will be administered topically to the mammalian eye and, in particular, dropped into the eye and/or injected into the mammalian eye approximately once, twice or three times daily.
- The duration of treatment administered in accordance with the present invention may range, for example, from a few weeks (at least one week) to a few months (at least one month), in particular, from 1 week to 8 months, preferably at least 2 weeks and less than 4 months and more preferably at least 3 weeks and less than 3 months. However, a prolonged treatment may be required. In particular, the treatment may last for one or several years or even for life, for example, in case of recurrence of the disorder(s) or disease(s) and especially of an ophthalmic condition.
- Of course, one of several additional active principle(s), and especially one of several additional compounds for treating eye disorders and/or diseases may be used in the methods of the invention or may be present in a composition, a medicament or a kit according to the invention, provided that they do not interact with the first and second active principles and—if present—with the third active principle, to provide adverse side effects.
- The invention relates, in particular, to the following embodiments:
- Point 1. A method for maintaining or improving the visual acuity and/or the field of vision in a patient in need of such treatment. Said method comprising: administering a drug combining: Ramipril (angiotensin converting enzyme inhibitor)—folic acid. This drug maintains or improves visual acuity and the field of vision.
- Point 2. The method according to point 1, wherein said drug is a cellprotector, a neuroproteetor and/or a retinoprotector.
- Point 2a. The method according to point 1, wherein said drug is associated with one or several compounds chosen among L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, magnesium, potassium, glucose, non steroid anti-inflammatory drug, steroidal anti-inflammatory drug, and amino-acids, for example, leucine (especially acetyl-leucine), beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents and anti-VEGF agents.
- Point 3. The method according to point 1, wherein said drug is associated with one or several compounds chosen among L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, magnesium, potassium, glucose, non steroid anti-inflammatory drug, steroidal anti-inflammatory drug, and amino-acids, for example, leucine (especially acetyl-leucine). Point 4. The method according to point 1, wherein said drug is administered orally.
- Point 5. The method according to point 1, wherein said drug is administered parenterally.
- Point 8. The method according to point 5, wherein said drug is administered topically to the eye (ophthalmic solution; ointment).
- Point 7. The method according to point 1, wherein said patient has glaucoma or glaucoma neuropathy.
- Point 8. The method according to point 1, wherein said patient has an hereditary dystrophy of the retina, for example, a pigmentary retinopathy or a stargardt's disease,
- Point 9. The method according to point 1, wherein said patient has a diabetic retinopathy.
- Point 10. The method according to point 1, wherein said patient has an age related macular degeneration with or without choroidal new vessels.
- Point 11. The method according to point 1, wherein said patient has an uveitis, papillitis.
- Point 12. The method according to point 1, wherein said patient has an ammetropia, for example, a myopia, a presbyopia or a hypermetropia.
- Point 13. The method according to point 1, wherein said patient has a retinal arterial or vein occlusion.
- Point 14. The method according to point 1, wherein normal subject has a physiologic decreased vision.
- Point 15. The method according to point 1, wherein said patient has corneal disorders and dry eye syndrome and/or keratoconjunctivitis caused by dry eye syndrome.
- Point 16. The method according to point 1, wherein said patient has an ocular allergy (conjunctivitis).
- Point 17. The method according to point 1, wherein said patient has general disorder such as: arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (multiple sclerosis, Alzheimer, Parkinson . . . ), rheumatism, general inflammatory and immune conditions, infections (for example, viral and especially HIV infection, bacterial infection and/or parasitic infection) and cancer (for example, carcinoma, especially adeno-carcinoma).
- The invention will be illustrated further by the description of clinical examples which, of course, are not limiting in nature.
- In the case of the clinical cases disclosed below, the active principles, in particular, Ramipril and folic acid ware administered continuously (i.e., at least once a day), in an oral form of 1.26 mg per day for Ramipril and 5 mg per day for folic acid or in a topical form.
- The clinical observations disclosed below are, of course provided solely by way of illustration and do not in any way limit the scope of the invention. It is notable that equivalent observations were made in “normal” patients, which do not present any ocular pathology (in particular, aging patients above the age of 60), to whom the medicament was administered; these patients noticed an improvement of their vision, in particular, aging individuals regained the mean sensitivity that they experienced when they were much younger.
- GLAUCOMA AMD GLAUCOMATOUS NEUROPATHY: the administration of the combination of Ramipril and folic acid in oral or topic form induces improvement in the visual function (visual acuity or visual field) and decreased intraocular pressure in 18 individuals.
- MYOPIA: 3 patients were tested, The patient's vision was tested before and after the first eye-drop formulation was administered. 2 hours later, the patient's unaided distance vision improved. Wearing distance-corrected glasses, the patient vision improved.
- PRESBYOPIA: 5 patients were tested. The patient's near vision was tested before treatment. 2 hours after this treatment the patient's near vision increased.
- AMMETROPIA: improvement of near and distance vision 2 hours after treatment.
- HEREDITARY DYSTROPHY OF THE RETINA AND PIGMENTARY EPITHELIUM:
- 1-Retinitis pigmentosa: this disorder corresponds to a dystrophy in the cones and rods. It is characterized by the appearance of night blindness in infancy or adolescence, progressive contractions of the peripheral field of vision and results in a substantial loss in visual acuity or even blindness by adulthood. Four patients were treated orally or topically and their visual acuity improved.
- 2-Stargardt's disease:
- Two patients were treated visual. Acuity improved from 2 to 4/10.
- AGE RELATED MACULAR DEGENERATION (ARMD): 12 patients were tested. The majority of patients presenting an age-related macular degeneration with or without sub-retinal neovessels treated with the combination Ramipril and folic-acid experienced improved visual acuity.
- DIABETIC RETINOPATHY: All 10 patients were treated with the combination Ramipril and folic acid improved their vision and ocular fundus appearance.
- KERATOCONJUNCTIVITIS BY DRY EYE: 2 patients received this treatment and their conditions were improved.
- The term “visual function” as used herein should be understood to refer more particularly but not in a limiting manner to visual acuity or the field of vision or, as is preferable, to both at once. The invention thus concerns, in an embodiment, a cellprotective, neuroprotective and retinoprotective ophthalmologic drug that can interrupt the process of degradation of visual function and even reverse its course.
- The invention is not limited to the use of the Ramipril and folic acid combination for the treatment of the disorders mentioned above. Especially, the combination of Ramipril and folic acid can also be associated, for example, with one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B, L-arginine, w-3 fatty acids, magnesium, potassium, glucose, and amino-acids (for example, leucine and especially acetyl-leucine).
- CANCER: an eighty old woman presented with an adeno-carcinoma (cancer) in the tongue. She received the same treatment (i.e., ramipril and folic acid), which was administered by the oral route and after four months of daily treatment, the volume of the tumour was decreased by about 30%.
- It appears that the beneficial effect achieved by the folic acid and Ramipril combination may be explained by the increase of nitric oxide (NO) bioavailability in a cell. This is only a hypothesis and must be further explored.
- The Increase of NO bioavailability improves endothelial function, significantly reduces endothelial dysfunction, acts against oxidative stress, significantly reduces inflammation, has antithrombotic activity and inhibits blood clot formation.
- Ramipril as an ACEI or Ramiprilat reduces degradation of bradykinin stimulating NO reduction. Long term bradykinin stimulation enhances the release of NO. causing vasodilatation. Ramipril (or Ramiprilat) drastically reduces superoxide production and oxidative stress. But NO formation is critically dependant on the availability of the cofactor H4B which stimulates the conversion of L-arginine to L-citrulline and NO by NOS (NO synthase). Folic acid or folate (vitamin B8) stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and thus enhances the half-life of NO.
- Impaired endothelial NO (eNO) activity is an early marker for cardiovascular disease. Most risk factors for atherosclerosis are associated with impaired endothelium dependent vasodilatation due to reduced NO production. Folate not only reduces plasma homocysteine levels but also enhances eNO synthesis and shows anti-inflammatory actions. It stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and this cellprotective, neuroprotective and retinoprotective ophthalmologic drug that can interrupt the process of degradation of visual function and even reverse its course.
- The invention is not limited to the use of the Ramipril and folic acid combination for the treatment of the disorders mentioned above. Especially, the combination of Ramipril and folic acid can also be associated, for example, with one or several compounds chosen among vitamin B12, vitamin B6, Vitamin C, H4B, L-arginine, w-3 fatty acids, magnesium, potassium, glucose, and amino-acids (for example, leucine and especially acetyl-leucine).
- CANCER: an eighty old woman presented with an adeno-carcinoma (cancer) in the tongue. She received the same treatment (i.e., ramipril and folic acid), which was administered by the oral route and after four months of daily treatment, the volume of the tumour was decreased by about 30%.
- It appears that the beneficial effect achieved by the folic acid and Ramipril combination may be explained by the increase of nitric oxide (NO) bioavailability in a cell. This is only a hypothesis and must be further explored.
- The increase of NO bioavailability improves endothelial function, significantly reduces endothelial dysfunction, acts against oxidative stress, significantly reduces inflammation, has antithrombotic activity and inhibits blood clot formation.
- Ramipril as an ACEI or Ramiprilat reduces degradation of bradykinin stimulating NO reduction. Long term bradykinin stimulation enhances the release of NO, causing vasodilatation. Ramipril (or Ramiprilat) drastically reduces superoxide production and oxidative stress. But NO formation is critically dependant on the availability of the cofactor H4B which stimulates the conversion of L-arginine to L-citrulline and NO by HOS (NO synthase). Folic acid or folate (vitamin B9) stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and thus enhances the half-life of NO.
- Impaired endothelial NO (eNO) activity is an early marker for cardiovascular disease. Most risk factors for atherosclerosis are associated with impaired endothelium dependent vasodilatation due to reduced NO production. Folate not only reduces plasma homocysteine levels but also enhances eNO synthesis and shows anti-inflammatory actions. It stimulates endogenous H4B regeneration, a cofactor necessary for eNO synthesis, inhibits intracellular superoxide generation, and this enhances the half-life of NO. Vitamin C augments eNO synthesis by increasing intracellular H4B. The ability of folate to augment eNO generation is independent of its capacity to lower plasma homocystein levels.
- In conclusion, it is proposed that folic acid, vitamin c, w-3 fatty acids, H4B, L arginine and magnesium, augment the activity of Ramipril and thus may act in synergy with Ramipril by enhancing NO production. This would explain why this association is more efficient to prevent or to treat some ocular pathologies and presents as a more cellprotective, neuro and retinoprotective than these drugs used alone.
- Hence, the common mechanism by which Ramipril, folic acid, vitamin c, w-3fatty acids, H4B, L arginine and magnesium, bring about their beneficial actions in various vascular and ocular diseases is thought to be by enhancing eNO production.
- In view of the clinical observations, the combination of Ramipril and folic acid and, optionally vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, H4B, L-arginine, potassium, magnesium, glucose and/or and amino-acids (for example, leucine and especially acetyl-leucine) could be judicious for a novel approach in the prevention and management of various conditions such as eye conditions (as disclosed herein) arterial hypertension, hyperlipidemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (multiple sclerosis, Alzheimer disease, Parkinson disease, etc . . . ), rheumatism, general inflammatory and immune conditions, infections (viral, bacterial and/or parasitic infections), especially HIV infections, and cancer.
Claims (41)
1-32. (canceled)
33. A composition comprising at least two active principles selected from the group consisting of an angiotensin-converting enzyme inhibitor (ACEI), folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof and mixtures thereof.
34. The composition according to claim 33 , which comprises:
a) a first active principle, which consists essentially of an ACEI; and
b) a second active principle, which is selected from the group consisting of folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, one of their pharmaceutically acceptable salts, derivatives thereof, and mixtures thereof.
35. The composition according to claim 34 , further comprising a third active principle, which is selected from the group consisting of L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist, agents, anti-VEGF agents, and mixtures thereof.
36. The composition according to claim 33 , wherein the ACEI comprises Ramipril, Ramiprilat, one of their pharmaceutically acceptable salts or any derivative of Ramipril or Ramiprilat that can liberate Ramipril or Ramiprilat into an animal to which the active principle is administered, or a mixture thereof.
37. The composition according to claim 34 , wherein the first active principle is ramipril and the second active principle is folic acid or a mixture of (i) folic acid, and (ii) magnesium or a pharmaceutically acceptable salt thereof and/or potassium or a pharmaceutically acceptable salt thereof.
38. The composition according to claim 33 , which comprises:
a) a first active principle, which is selected from the group consisting of: folic acid, folate, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
b) a second active principle, which is selected from the group consisting of: magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, B4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
39. The composition according to claim 38 , further comprising a third active principle, which is chosen among: anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, one of their pharmaceutically acceptable salts or a derivative thereof and mixtures thereof.
40. The composition according to claim 38 , wherein the second active principle comprises:
magnesium (or a pharmaceutically acceptable salt thereof) and/or potassium (or a pharmaceutically acceptable salt thereof) and/or glucose and/or amino-acids (for example, leucine, especially acetyl-leucine) and/or L-arginine, and
optionally, an active principle chosen from H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof and mixtures thereof.
41. The composition according to claim 38 , wherein
the first active principle comprises folic acid and/or folate; and/or
the second active principle comprises magnesium (or a pharmaceutically acceptable salt thereof), potassium (or a pharmaceutically acceptable salt thereof), glucose and a leucine (especially a leucine and, in particular, an acetyl-leucine), and optionally L-arginine.
42. The composition according to claim 33 , which comprises:
a) a first active principle, which is selected, from the group consisting of: glucose, one of its pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
b) a second active principle, which is selected from the group consisting of: magnesium, potassium, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof, and
c) a third active principle, which comprises an amino acid and, in particular, a leucine (especially an acetyl-leucine) or a pharmaceutically acceptable salt thereof or a derivative thereof.
43. The composition according to claim 42 , which comprises:
a)—glucose as a first active principle;
b)—a mixture of magnesium (or one of its pharmaceutically acceptable salts) and potassium (or one of its pharmaceutically acceptable salts) as second active principle; and
c)—a leucine as third active principle.
44. The composition according to claim 33 , wherein the leucine is an N-acetyl-DL-leucine.
45. The composition according to claim 33 , which is in a form appropriate for enteral, especially oral, parenteral, especially intravenous, intramuscular or subcutaneous, transdermal, or topical administration, especially for topical administration to the eye, including intravitreal injection, or for sub-tenonian administration.
46. The composition according to claim 45 , which is in the form of a tablet, a solution, a lotion, drops, a cream or an ointment.
47. The composition according to claim 46 , which is in the form of an ophthalmic solution or eye drops.
48. A kit comprising:
at least two active principles selected from the group consisting of an angiotensin-converting enzyme inhibitor (ACEI), folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative, and mixtures thereof; and
instructions for using said kit,
wherein said active principles are associated in the same composition or wherein at least two of these active principles are in separate compositions.
49. The kit according to claim 48 , which comprises:
a combination of a first active principle, and
a second active principle, and,
a third active principle, and
instructions for using said kit,
wherein the first active principle, the second active principle and—if present—the third active principle, are present in the same composition or wherein at least two of these active principles are present in separate compositions.
50. The kit according to claim 48 , which comprises:
a first active principle, which consists essentially of an ACEI; and
a second active principle, which is selected from the group consisting of folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, one of their pharmaceutically acceptable salts, derivatives thereof, and mixtures thereof.
51. The kit according to claim 48 , further comprising a third active principle, which is selected from the group consisting of L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, and mixtures thereof.
52. The kit according to claim 48 , wherein the ACEI comprises Ramipril, Ramiprilat, one of their pharmaceutically acceptable salts or any derivative of Ramipril or Ramiprilat that can liberate Ramipril or Ramiprilat into an animal to which the active principle is administered, or a mixture thereof.
53. The kit according to claim 48 , wherein the first active principle is ramipril and the second active principle is folic acid or a mixture of (i) folic acid, and (ii) magnesium or a pharmaceutically acceptable salt thereof and/or potassium or a pharmaceutically acceptable salt thereof.
54. The kit according to claim 48 , which comprises:
a) a first active principle, which is selected from the group consisting of: folic acid, folate, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
b) a second active principle, which is selected from the group consisting of: magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
55. The kit according to claim 54 , further comprising a third active principle, which is chosen among: anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
56. The kit according to claim 54 , wherein the second active principle comprises:
magnesium (or a pharmaceutically acceptable salt thereof) and/or potassium (or a pharmaceutically acceptable salt thereof) and/or glucose and/or amino-acids (for example, leucine, especially acetyl-leucine) and/or L-arginine, and
optionally, an active principle chosen from H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
57. The kit according to claim 54 , wherein
the first active principle comprises folic acid and/or folate; and/or
the second active principle comprises magnesium (or a pharmaceutically acceptable salt thereof), potassium, (or a pharmaceutically acceptable salt thereof), glucose and a leucine (especially a leucine and, in particular, an acetyl-leucine), and optionally L-arginine.
58. The kit according to claim 48 , which comprises:
a) a first active principle, which is selected from the group consisting of: glucose, one of us pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof; and
b) a second active principle, which is selected from the group consisting of: magnesium, potassium, one of their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof, and
c) a third active principle, which comprises an amino acid and, in particular, a leucine (especially an acetyl-leucine) or a pharmaceutically acceptable salt thereof or a derivative thereof.
59. The kit according to claim 58 , which comprises:
a)—glucose as a first active principle;
b)—a mixture of magnesium (or one of its pharmaceutically acceptable salts) and potassium (or one of its pharmaceutically acceptable salts) as second active principle; and
c)—a leucine as third active principle.
60. A method of preventing and/or treating one or several disease(s) or disorder(s) in an animal in need thereof said method comprising administering to said animal at least two active principles comprising an angiotensin-converting enzyme inhibitor (ACEI), folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
61. The method according to claim 60 , further comprising administering a third active principle, which is selected from the group consisting of L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, and mixtures thereof, wherein said active principles are administered separately or not.
62. The method according to claim 60 , wherein the disease(s) or disorder(s) is(are) chosen from: cancers (especially carcinoma or adeno-carcinoma), arterial hypertension, hyperlipemia, coronary heart disease, atherosclerosis, diabete, neurodegenerative conditions (especially multiple sclerosis, Alzheimer disease and/or Parkinson disease), rheumatism, general inflammatory and immune conditions and infections (especially viral and especially HIV infection, bacterial infection and/or parasitic infection), ophthalmologic condition(s) chosen from:
glaucoma neuropathy or glaucoma;
macular degeneration and, in particular, age related macular degeneration, with or without choroidal new vessels;
diabetic retinopathy
degenerative chorio retinopathy;
hereditary dystrophy of the retina, for example, pigmentosa retinopathy or Stargardt's disease;
retinal arterial or vein occlusion;
uveitis;
papillitis;
ammetropia, for example, myopia, presbyopia or hypermetropia;
corneal disorders, for example, keratoconjunctivitis (especially keratoconjunctivitis caused by eye dryness or keratoconjunctivitis sicca), dry eye or Fuchs' corneal dystrophy;
ocular allergy (or conjunctivitis); and
natural reduction in visual acuity and/or in visual field and, in particular, physiologic visual decline.
63. A method for maintaining or improving vision and, in particular, the visual acuity and/or the field of vision in an animal in need thereof, said method comprising administering to said animal at least two active principles selected from the group consisting of an angiotensin-converting enzyme inhibitor (ACEI), folic acid, folate, magnesium, potassium, glucose, amino-acids, a leucine, an acetyl-leucine, L-arginine, tetrahydrobiopterin (H4b), vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-vascular endothelial growth factor (anti-VEGF) agents, their pharmaceutically acceptable salts or a derivative thereof, and mixtures thereof.
64. The method according to claim 63 , further comprising administering a third active principle which is selected from the group consisting of L-arginine, H4b, vitamin B6, vitamin B12, vitamin C, w-3 fatty acids, anti-inflammatory agents, beta-blocking agents, adrenaline, noradrenaline, alpha adrenergic agonist agents, anti-VEGF agents, and mixtures thereof, wherein said active principles are administered separately or not.
65. The method of claim 63 , wherein the animal has one or several ophthalmologic condition(s) chosen from:
glaucoma neuropathy or glaucoma;
macular degeneration and, in particular, age related macular degeneration, with or without choroidal new vessels;
diabetic retinopathy
degenerative chorio retinopathy;
hereditary dystrophy of the retina, for example, pigmentosa retinopathy or Stargardt's disease:
retinal arterial or vein occlusion;
uveitis;
papillitis;
ammetropia, for example, myopia, presbyopia or hypermetropia;
corneal disorders, for example, keratoconjunctivitis (especially keratoconjunctivitis caused by eye dryness or keratoconjunctivitis sicca), dry eye or Fuchs' corneal dystrophy;
ocular allergy (or conjunctivitis); and
natural reduction in visual acuity and/or in visual field and, in particular, physiologic visual decline;
and/or is aged.
66. The method of claim 63 , wherein said composition(s) comprising the active principle(s) and especially the first and/or the second and/or the third active principle is(are) cellprotector, neuroprotector and/or retinoprotector composition(s).
67. The method of claim 63 , wherein said active principle(s) and especially the first and/or the second active principle and/or the third active principle is(are) administered topically, in the form of an ophthalmic solution, eye drops or an ointment, and/or via intravitreal injection.
68. The method of claim 63 , wherein said active principle(s) and especially the first active principle and/or the second active principle and/or the third active principle is(are) administered by the enteral route, especially orally.
69. The method of claim 63 , wherein said active principle(s) and especially the first active principle and/or the second active principle and/or the third active principle is(are) administered by the parenteral route, especially by the intravenous, intramuscular or subcutaneous route.
70. The method of claim 63 , wherein said active principle(s) and especially the first active principle and/or the second active principle and/or the third active principle is(are) administered topically, in the form of an ophthalmic solution or eye drops.
71. The method of claim 63 , wherein
Ramipril or Ramiprilate is administered topically in a concentration of 0.5 to 5 % or 0.5 to 3%, or 0.5%, 1% or 2%, or orally, in an amount of 0.5 to 5 mg/day or 1 to 2 mg/day or 1.25 mg/day to a human; and/or
folic acid or folate is administered topically in a concentration of 0.5 to 5 % or 0.5 to 3% or 0.5%, 1% or 2%, and/or orally, in an amount of 2 to 8 mg/day or 4 to 6 mg/day or 5mg/day to a human.
72. A composition consisting essentially of at least two active principles chosen among an angiotensin-converting enzyme inhibitor (ACEI), such as Ramipril or Ramiprilat, and anti-inflammatory agents, their pharmaceutically acceptable, salts or a derivative thereof and mixtures thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TN2010/0566 | 2010-12-03 | ||
TNP2010000566A TN2010000566A1 (en) | 2010-12-03 | 2010-12-03 | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
PCT/IB2011/000960 WO2012073077A1 (en) | 2010-12-03 | 2011-05-06 | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/000960 A-371-Of-International WO2012073077A1 (en) | 2010-12-03 | 2011-05-06 | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/599,223 Continuation US20150133455A1 (en) | 2010-12-03 | 2015-01-16 | Folic acid – ramipril combination: cell protective, neuroprotective and retinoprotective ophtalmoligic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130317036A1 true US20130317036A1 (en) | 2013-11-28 |
Family
ID=54696113
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/991,286 Abandoned US20130317036A1 (en) | 2010-12-03 | 2011-05-06 | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
US14/599,223 Abandoned US20150133455A1 (en) | 2010-12-03 | 2015-01-16 | Folic acid – ramipril combination: cell protective, neuroprotective and retinoprotective ophtalmoligic compositions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/599,223 Abandoned US20150133455A1 (en) | 2010-12-03 | 2015-01-16 | Folic acid – ramipril combination: cell protective, neuroprotective and retinoprotective ophtalmoligic compositions |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130317036A1 (en) |
EP (1) | EP2646010B1 (en) |
JP (1) | JP5897592B2 (en) |
CN (1) | CN103338758B (en) |
AU (1) | AU2011334617B2 (en) |
CA (1) | CA2819628C (en) |
ES (1) | ES2770410T3 (en) |
PL (1) | PL2646010T3 (en) |
RU (1) | RU2602738C2 (en) |
TN (1) | TN2010000566A1 (en) |
WO (1) | WO2012073077A1 (en) |
ZA (1) | ZA201304026B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9301933B2 (en) | 2011-09-20 | 2016-04-05 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2010000251A1 (en) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR |
TN2016000259A1 (en) | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
LT3416631T (en) * | 2016-08-11 | 2019-08-26 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
CN108452309B (en) * | 2018-03-05 | 2019-08-23 | 佳木斯大学附属第一医院 | It is a kind of for preventing or the pharmaceutical composition for treating optic neuritis and preparation method thereof |
RU2717343C1 (en) * | 2019-03-01 | 2020-03-23 | Евгений Владимирович Плотников | Agent possessing cytoprotective action |
CN114917345A (en) * | 2021-04-07 | 2022-08-19 | 北京蛋白质组研究中心 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
AU2022300058A1 (en) * | 2021-06-24 | 2024-02-01 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Application of folic acid derivatives in preparation of drugs for treating contact lens discomfort and xerophthalmia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099724A1 (en) * | 2001-11-16 | 2003-05-29 | Turner Oliver E. | Compounds for prevention of diabetic retinopathy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804603A (en) | 1993-11-26 | 1998-09-08 | National Science Council | Synthesized β-adrenergic blockers derivatives of guaiacol |
WO1999062560A1 (en) * | 1998-06-05 | 1999-12-09 | Warner-Lambert Company | Stabilization of compositions containing ace inhibitors using magnesium oxide |
US6207190B1 (en) * | 1998-08-13 | 2001-03-27 | Chronorx, Llc | Dosage forms for the treatment of the chronic glaucomas |
BR0011714A (en) * | 1999-06-16 | 2002-03-05 | Elyes Ben Mohamed Raouf Rekik | Neuroprotective and retinoprotective ophthalmic medication and use of an active drug |
US7335803B2 (en) | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6583152B2 (en) * | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
WO2003013434A2 (en) * | 2001-08-06 | 2003-02-20 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
JP2008509169A (en) * | 2004-08-10 | 2008-03-27 | メディキュア・インターナショナル・インコーポレーテッド | Combination therapy using vitamin B6-related compounds and ACE inhibitors and use thereof for the treatment of diabetic diseases |
WO2006085128A1 (en) * | 2005-02-09 | 2006-08-17 | Wockhardt Limited | Cardiovascular therapeutic combinations |
WO2007014308A1 (en) * | 2005-07-27 | 2007-02-01 | Achillion Pharmaceuticals, Inc. | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents |
ES2300188B1 (en) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | BICAPA COMPRESSED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS. |
CN101176788B (en) * | 2006-11-11 | 2011-06-15 | 深圳奥萨医药有限公司 | Pharmaceutical composition for ACE restrainer/uretica/folic acid, and uses thereof |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
CN101396561A (en) * | 2007-09-28 | 2009-04-01 | 北京华安佛医药研究中心有限公司 | Use of composition containing ACEI in preparing medicine for treating hyperhomocysteinemia injury and related diseases thereof |
CN101590084B (en) * | 2008-05-29 | 2012-12-05 | 北京奥萨医药研究中心有限公司 | Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts |
CN101322743A (en) * | 2008-08-01 | 2008-12-17 | 李翔 | Formulation capable of repairing lesion and damnification of eye and improving asthenopia and preparation thereof |
CA2836445C (en) * | 2010-06-25 | 2019-06-11 | Global Healthcare Focus, Llc | Methods of treating optic disorders |
-
2010
- 2010-12-03 TN TNP2010000566A patent/TN2010000566A1/en unknown
-
2011
- 2011-05-06 US US13/991,286 patent/US20130317036A1/en not_active Abandoned
- 2011-05-06 RU RU2013125146/15A patent/RU2602738C2/en active
- 2011-05-06 PL PL11724029T patent/PL2646010T3/en unknown
- 2011-05-06 EP EP11724029.1A patent/EP2646010B1/en active Active
- 2011-05-06 CN CN201180066768.3A patent/CN103338758B/en not_active Expired - Fee Related
- 2011-05-06 AU AU2011334617A patent/AU2011334617B2/en not_active Ceased
- 2011-05-06 CA CA2819628A patent/CA2819628C/en active Active
- 2011-05-06 JP JP2013541436A patent/JP5897592B2/en not_active Expired - Fee Related
- 2011-05-06 WO PCT/IB2011/000960 patent/WO2012073077A1/en active Application Filing
- 2011-05-06 ES ES11724029T patent/ES2770410T3/en active Active
-
2013
- 2013-05-31 ZA ZA2013/04026A patent/ZA201304026B/en unknown
-
2015
- 2015-01-16 US US14/599,223 patent/US20150133455A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099724A1 (en) * | 2001-11-16 | 2003-05-29 | Turner Oliver E. | Compounds for prevention of diabetic retinopathy |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9301933B2 (en) | 2011-09-20 | 2016-04-05 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
US9579308B2 (en) | 2011-09-20 | 2017-02-28 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
Also Published As
Publication number | Publication date |
---|---|
US20150133455A1 (en) | 2015-05-14 |
EP2646010A1 (en) | 2013-10-09 |
JP2013544275A (en) | 2013-12-12 |
CN103338758B (en) | 2017-12-12 |
WO2012073077A1 (en) | 2012-06-07 |
CA2819628A1 (en) | 2012-06-07 |
AU2011334617A1 (en) | 2013-06-20 |
RU2013125146A (en) | 2015-01-10 |
TN2010000566A1 (en) | 2012-05-24 |
AU2011334617B2 (en) | 2017-01-12 |
RU2602738C2 (en) | 2016-11-20 |
AU2011334617A2 (en) | 2013-08-01 |
ZA201304026B (en) | 2014-02-26 |
JP5897592B2 (en) | 2016-03-30 |
ES2770410T3 (en) | 2020-07-01 |
EP2646010B1 (en) | 2019-11-13 |
CA2819628C (en) | 2019-12-03 |
CN103338758A (en) | 2013-10-02 |
PL2646010T3 (en) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220184057A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
AU2011334617B2 (en) | Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
EP2262476B1 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
JP5959507B2 (en) | N-acetyl-DL-leucine, a neuroprotective and retinal protective drug | |
KR20040100844A (en) | Combination of brimonidine and timolol for topical ophthalmic use | |
CN103747786A (en) | Fixed dose combination of bimatoprost and brimonidine | |
US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
CN113164451A (en) | Methods and compositions for treating glaucoma and related disorders | |
KR20230098630A (en) | Low dose synergistic ophthalmic compositions effective for the prevention, control and eradication of presbyopia | |
US20200188405A1 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
RU2607291C1 (en) | Method of treating primary glaucoma in patients with accompanying arterial hypertension | |
WO2023001176A1 (en) | Method for treating myopia with vinpocetine | |
TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
JP2021517139A (en) | Usage of Selective SYK Inhibitors and Pharmaceutical Compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |